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Abstract
The goal of radiation therapy is to eradicate the cancer cells by delivery of a
high enough dose of ionizing radiation to the tumour, while at the same time
sparing the surrounding healthy tissue. This dual purpose has motivated the
development of hadron therapy.
The sharp dose deposition from protons in a medium has some clear ad-
vantageous aspects for use in cancer treatment. When charged particles, for
instance protons, traverse matter, most of their energy are deposited at the
end of their range, causing a sharp peak, the Bragg peak, at a depth deter-
mined by the proton range in the medium. This range is a function of the
initial proton energy and of the characteristics of the traversed medium.
Treatment techniques for delivery of proton therapy have evolved from pas-
sive scattering systems into sophisticated beam spot scanning techniques,
providing additional degrees of freedom for the treatment delivery. In order
to deliver a precise and efficient treatment to a patient, it is vital to calculate
the dose distribution from protons applying an accurate calculation of the
proton range in the patient. A well defined range of the proton beam is not
only the characteristic that makes protons beneficial for cancer treatment,
it is also the characteristic that makes the method vulnerable for uncertain-
ties. Computer simulations are frequently used to estimate the proton range
and the associated dose deposition in a patient. The Monte Carlo simulation
method is optimal for estimating particle transport in matter, and thus it
can serve as the tool to enable detailed knowledge about dose deposition in
a medium, and hence in a patient. However, Monte Carlo simulations can
be time consuming and thus not compatible with the clinical demands. In
most dose planning programs applied in the clinical routine, somewhat sim-
pler algorithms than Monte Carlo simulations are used to create the dose
distributions in treatment plans. These algorithms calculate the dose distri-
bution partly based on mathematical models for dose distribution and partly
based upon input from Monte Carlo simulations and the calculated dose is
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calculated from a geometry input generated by the attenuation of photons
in a CT voxel geometry.
The purpose of this project has been to apply Monte Carlo software to
simulate a proton beam resembling a therapeutic beam, and to study the
interactions of this beam in phantoms of various design. The simulations
were produced with FLUKA Monte Carlo code version 2011 2b. Further the
purpose has been to apply Varian Eclipse proton planning (version 11) soft-
ware to create treatment plans on similar phantoms, in order to study the
differences between a time-effective, clinically optimized tool and an accu-
rate, yet time consuming, Monte Carlo simulation tool.
A fundamental criteria for a therapeutic beam is that the beam must have
the ability to deliver a homogeneous dose to an extended volume. To meet
this criteria, the energy of the applied protons must be spread out in order
to create a plateau of dose covering the target volume, which is the tumour
with some specified margins. This implies that an otherwise monoenergetic
beam needs to be energy modulated in order to produce a weighted energy
spectrum, resulting in a spread-out Bragg peak (SOBP). In this project, two
different approaches were followed in order to obtain a dose deposition with
a flat dose plateau at the desired depth. By (1) passively modulating the
beam range by inserting material into the simulated beamline, which is the
equivalent of the use of a range modifier positioned in the beamline, and by
(2) actively modulating the proton energy from the beam source. The result-
ing dose distributions from these two approaches showed that the dose falloff
at the distal part of the target volume was sharper with the active energy
modulation approach than when passively using material to modulate the
beam energy.
In treatment planning, the stoichiometric method is used to obtain an ap-
proximated relation between the CT deduced Hounsfield Unit value and the
proton stopping power. With the stoichiometric method the CT value of a
given human tissue is coupled to the proton stopping power, calculated using
known physical parameters of the medium such as physical density, elemen-
tal composition and mean ionization energy. Since the CT Hounsfield Unit
value and the proton stopping power reflects different physical interactions,
ie attenuation of a photon beam versus energy deposition of a proton beam,
this relation is not straightforward or one-to-one in general. Thus, there is
an uncertainty in a proton range calculation based on CT images. With
Monte Carlo codes for particle transport, one can model the geometry in an
accurate way, assigning materials with its elemental composition and their
iv
physical properties.
The final goal of this project was obtained by the use of a commercial treat-
ment planning system to produce simple treatment plans, and further; to
compare the dose profiles to similar treatment plans created with a Monte
Carlo simulated beam and geometry. The overall agreement between the two
calculation methods were adequate, especially with respect to dose coverage
within the defined target volume. However, when introducing different ma-
terials such as bone, air and aluminium into the geometry, the differences
between the two methods became apparent and it illustrates the tentative
limitations of a fast, clinical optimized, dose planning tool compared with a
more accurate and detailed, hence tentatively slower, Monte Carlo simulation
tool.
v
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Chapter 1
Introduction
Cancer is a generic term for a large group of diseases that can affect any
part of the body. Two defining features of cancer are; 1) the occurrence of
abnormal cells that divide without control, and; 2) the cancer cells have a
metastatic feature, and thus, if not treated, these may invade other organs
and healthy tissue. Cancer is a leading cause of death worldwide, accounting
for 7.6 million deaths in 2008 [1]. About half of all cancer patients in Norway
are treated with radiation therapy [2]. The number of patients undergoing
radiation therapy in Norway in 2010 was 11370 [3].
The goal of radiation therapy is to inactivate cancer cells by delivery of
a high enough dose to the tumor, while at the same time spare the surround-
ing healthy tissue. Ever since Roentgens’ discovery of X-rays in 1895, efforts
have been made to reach this goal. Especially the development of sophisti-
cated medical imaging modalities, such as CT, MRI and PET, has provided
a huge leap forward in better dose delivery in radiation therapy.
The most common and widespread modality within radiation therapy is ex-
ternal radiation therapy, ie irradiation of a patient from the outside, and
this with the use of photons. Photons in the MeV energy range are produced
in medical linear accelerators and aimed towards the target volume. Follow-
ing the development of better imaging techniques and improved computing
power, innovations such as Intensity-Modulated Radiation Therapy (IMRT)
and Volumetric-Modulated Arc Therapy (VMAT) has made it possible to
produce quite complex dose plans optimized in order to deliver the desired
dose to the tumour, and at the same time minimize the dose to healthy tissue
and organs surrounding the tumour.
In particle therapy, the physical properties of charged particles, such as pro-
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tons or heavier ions are utilized to irradiate the defined target volume. As
early as 1946, the American physicist Dr. Robert Wilson suggested that pro-
ton beams could be used to treat cancer. He argued that protons had thera-
peutic advantages over photons due to their superior depth-dose characteris-
tics [4] [5]. The first proton therapy facilities where mainly physics research
laboratories. In Scandinavia, Uppsala University in Sweden treated their first
patient with protons as early as in 1957. Now there exists several dedicated
particle facilities for cancer treatment, most of them proton facilities. Many
future facilities are currently on the sketch board. In September 2013, the
Norwegian Minister of health announced that there will be established pro-
ton therapy facilities at the University Hospitals in the administrative health
regions in Norway.
Before the patient starts receiving radiation therapy treatment, many steps
have to be taken. Diagnostic medical imaging is performed, and an oncolo-
gist determines and defines the volume to be treated. A treatment planning
program is used to determine how the target volume should be irradiated
to achieve the best possible and satisfactory dose distribution. A 3D Com-
puted Tomography (CT) image set is imported into the treatment planning
program. The CT image consists of information from voxels representing the
X-ray radiation absorption in each voxel, each representing a position in the
part of the human body that is imaged. The dose distribution from the ra-
diation is calculated based on how the radiation interacts with the material,
applying a normalized Hounsfield Unit scale representing the density of the
material in each voxel.
An accurate calculation of the dose in the patient is one of the keys to a
successful treatment, especially during particle therapy where the longitu-
dinal dose gradients are very sharp. To make an accurate prediction of the
proton range in the human body valid during each treatment fraction can
be complicated due to varying physical properties in bone, gas and liquids,
and given the movement and variations that continuously occur in the hu-
man body. In this project a therapeutic proton beam will be modelled and
investigated using the FLUKA Monte Carlo simulation tool and the Varian
Eclipse Proton planning system, as applied at Haukeland University Hospital.
The overall goals for this project has been:
• Investigate how various materials such as bone, air and metal influence
the proton behavior in an otherwise homogeneous water phantom by
using a Monte Carlo simulated monoenergetic proton pencil beam.
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• With the same Monte Carlo program, create a spread-out Bragg peak
(SOBP) suitable for treatment of an extended volume inside the phan-
tom, by modulating the beam energy applying both passive and active
methods and then comparing the two methods.
• Creating basic treatment plans with the Varian Eclipse treatment plan-
ning software and with the FLUKA Monte Carlo tool and compare the
dose profiles and dose distributions calculated by the two methods when
irradiating a similar phantom in both systems.
In Chapter 2 the basic physics most relevant for radiation therapy is pre-
sented. This includes interactions of photons and charged particles with mat-
ter. In this chapter there will be a short summary of radiation biology and
the introduction of properties such as linear energy transfer (LET) and rel-
ative biological effectiveness (RBE).
Chapter 3 addresses radiation therapy. The chapter begins with a descrip-
tion of medical imaging used in radiation therapy. A short explanation about
photon therapy and its radiation source (the linear accelerator) and treat-
ment techniques is followed by a more comprehensive description of radiation
therapy with protons.
A general summary of the Monte Carlo method is presented in Chapter
4.
InChapter 5 the method, procedures and results of this project are outlined.
A short description of FLUKA and Eclipse, the software used to perform the
simulations, is given. Further, the simulation set-ups and the results of each
simulation are addressed.
Finally the conclusion and outlook is given in chapter 6.
All FLUKA Monte Carlo simulations shown in this thesis is produced by
the author, unless otherwise specified.
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Chapter 2
Radiation Physics
In this chapter the basic radiation physics most relevant for radiation therapy
will be presented. In general, as radiation penetrates matter, several interac-
tion mechanisms will be invoked and a variety of interactions can occur, all
depending on the characteristics of both the projectile traversing the matter
and the matter itself. Parameters most prominent in governing the inter-
action between radiation and matter are; the type of radiation, the energy
and electrical charge of the incoming radiation, and material properties such
as physical density, elemental composition and mean ionization energy. In
the case of irradiation with photons and charged particles, as is the situation
during radiation therapy, the electromagnetic interactions are the dominating
processes [6].
2.1 Interactions of Photons with Matter
A photon is a quantum gauge particle carrying electromagnetic energy, and
it is considered a neutral, massless particle. As the photon wavelength drops
to lower than about 10−11− 10−12 m the photon energy will be such that the
photon is in the X-ray and gamma (γ) part of the electromagnetic spectrum.
When passing through tissue, γ photons can be scattered and absorbed,
leading to a decrease in the radiation intensity. This attenuation of the beam
depends on the material it traverses. The intensity can be calculated by the
following formula:
I = I0e
−µx (2.1)
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Here I is the intensity at a certain depth, x, I0 is the initial intensity, x
[cm] is the thickness of the given material and µ [cm−1] is the linear at-
tenuation coefficient of the given material. The linear attenuation coefficient
decreases with energy of the γ and increases with atomic number and den-
sity of the absorber. The fraction of the photons transmitted is represented
by the factor e−µx. The photon beam will, to first order, not experience a
decrease in energy, only an attenuation of its intensity [7]. However, if a pho-
ton beam with an energy spectrum enters an absorber material, there will
be a “beam hardening” effect as a function of depth in the absorber; the low
energy photons being attenuated more rapidly than the high energy photons.
The three main processes leading to this attenuation of intensity are:
1. Photoelectric Effect
2. Compton Scattering
3. Pair Production
These processes will lead to either scattering or absorption of the photon,
thus removing the photon from its original path and, by this, reducing the
beam intensity. In figure 2.1 these three processes are illustrated. A fraction
of the photons in a photon beam will not undergo any interactions, due to the
stochastic and statistical nature of the fundamental interaction mechanisms
in nature, these photons will emerge unscattered beyond an absorber. The
probability, or cross section, of each of these processes depends on the photon
energy and the material it traverses, as can be seen in figure 2.2. The cross
section is used as a measure of the likelihood for a given interaction [6].
2.1.1 Photoelectric Effect
The incoming photon can interact with an orbital electron of the absorber
atom, causing the atom to eject the electron, called the photoelectron. The
photoelectron will have a kinetic energy determined by the photon energy
and by the electrons’ binding energy:
Ekin = Eγ − Ebinding (2.2)
The cross section for the photoelectric effect depends on the energy of the
photon and on the atomic number Z of the target material. The Z-dependence
goes as Z raised to between 4th to the 5th power [6] (p. 55). In diagnostic X-
ray images this effect is utilized, showing a sharp contrast between material
with different densities, such as bone and tissue.
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Figure 2.1: The three main interactions between photons and matter [8]. a)
The Photoelectric effect, b) Compton scattering, and c) Pair production.
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(a) Fundamental photon processes in lead.
(b) Fundamental photon processes in carbon.
Figure 2.2: The total photon cross section in (a) lead and (b) carbon as a
function of energy [9]. The cross section for the photoelectric process domi-
nates for the lowest energies, the keV range, while the cross section for pair
production becomes dominating for higher energies, starting at 1.022 MeV.
The Compton cross section reaches its maximum in the MeV range.
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2.1.2 Scattering
Compton scattering is the process where the photons get scattered off a
loosely bound electron. The kinematics of this process is given by the con-
servation of momentum and energy.
Eγ = hν,
hν ′ =
hν
1 + γ (1− cosθ) ,
Ee = hν − hν ′ = hν γ (1− cosθ)
1 + γ (1− cosθ)
(2.3)
The cross section for Compton scattering depends on the electron density of
the material traversed. Since the Z-dependence is not as strong as it is for
the photoelectric effect, imaging with photons in the Compton range will not
produce as sharp images as when using photons in the photoelectric energy
range. The difference between kV and MV images is illustrated in figure 2.3.
For therapeutic purposes, the energy of the photons is in the MeV region,
the energy region where the cross sections for Compton scattering and pair
production are dominating.
In addition to Compton scattering, photons can undergo what is known as
Rayleigh scattering or coherent scattering. In Rayleigh scattering the photon
passes near an atomic electron, setting it into oscillation. The electron will
reradiate the energy at the same frequency as the incident photon. Thus the
only effect of this process is the scattering of the photon at a small angle.
Rayleigh scattering occurs in high-Z materials and at low photon energies
[11].
2.1.3 Pair Production
When the photon energy is above 1.022 MeV, which is twice the rest mass of
an electron, the process of pair production can occur. This process involves
the production of an electron-positron pair. This interaction becomes domi-
nant as the photon energy increases above the threshold energy. This inter-
action becomes dominant as the photon energy increases above the threshold
energy, as can be seen in figure 2.2.
2.1.4 Neutron Production
In addition to the processes mentioned above, photons can also undergo in-
teractions producing neutrons. In photon therapy the photons will interact
9
Figure 2.3: Comparison of the kV CT slice (left) and MV cone beam CT
(right) of the head-and-neck patient for three orthogonal views [10].
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with the beamline components and with the patient’s body, producing sec-
ondary particles such as neutrons. Neutron production can be significant,
especially during radiation treatment applying techniques that involves col-
limation material in the beamline during irradiation, such as dynamic Multi
Leaf Collimators (MLCs) and/or having placed collimation devices and other
beamline equipment close to the patient [12] [13]. The advanced techniques
applying dynamic MLC motion, such as IMRT and VMAT, will be addressed
in chapter 3.
2.2 Interactions of Charged Particles with Mat-
ter
Charged particles interact with matter in a different way than photons. When
travelling through matter the projectile particle will either lose energy or be
deflected from its original path through the interactions that take place. This
results mainly from inelastic collisions with atomic electrons and elastic scat-
tering from nuclei. Other processes that can occur are emission of Čerenkov
radiation, nuclear reactions and bremsstrahlung, but these are rare com-
pared to the incident rate of collisions for charged particles such as protons.
Bremsstrahlung is the dominating process for electrons and positrons travers-
ing matter [6].
The interactions are mediated by the Coulomb force between the electric
field of the projectile particle and the electric field within the atom. In addi-
tion to the Coulomb force, nuclear reactions occur for heavier particles than
electrons and positrons. When a beam of protons pass through matter, for
instance a human body, there will be produced short-lived radioisotopes such
as 11C, 13N and 15O due to nuclear fragmentation processes.
In the case of the inelastic collisions, energy will be transferred from the pro-
jectile particle to the atom by ionization or excitation. The average energy
loss per unit path length, dE
dx
, is given by the Bethe-Bloch formula (equation
2.4). In figure 2.4 the stopping power in various media is plotted against mo-
mentum. The mass stopping power is the energy loss per unit track length
divided by the material density, − dE
dX
= −1
ρ
dE
dx
.
The Bethe-Bloch formula reads;
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−dE
dx
= 2piNar
2
emec
2ρ
Z
A
z2
β2
[
ln
(
2meγ
2v2Wmax
I2
− 2β2 − δ − 2C
Z
)]
(2.4)
re: classical electron radius = 2.817× 10−13 cm
me: electron mass = 511 MeV/c2
Na: Avogadros’s number = 6.022× 1023 mol−1
I: mean excitation potential
Z: atomic number of absorbing material
A: atomic weight of absorbing material
ρ: density of absorbing material
z: charge of incident particle in units of e
β: v
c
of the incident particle
γ: 1√
1−β2
δ: density correction
C: shell correction
Wmax: maximum energy transfer in a single collision
As can be seen from equation 2.4; when the traversing particle slows down,
the particle will deposit more energy per unit of length. The result of this
velocity dependency is that most of the particles’ energy will be deposited
at the end of the particle range, just before it stops completely. One will
see a sharp dose enhancement, the Bragg peak, as the particle stops. When
the particle beam is monoenergetic this peak will be very sharp. Due to the
statistic nature of the processes mentioned above there will be a distribution
in where monoenergetic particles come to rest, some particles will stop before
others, this is referred to as range straggling, thus giving the Bragg peak a
finite thickness. The proton is a nuclear particle with charge +1e and it
has a mass of 938 MeV/c2. In figure 2.5 the longitudinal dose profile for
proton beams of three different energies are displayed. Figure 2.6 shows the
dose deposition in 2D color wash of a 150 MeV proton beam simulated in
FLUKA. As seen in the Bethe-Bloch formula, this process also depends on
the square of the particle charge. Thus for heavier nuclei such as 12C this
effect is even more pronounced [11] [15].
Multiple Coulomb Scattering
As the charged particle traverses the matter it can undergo repeated elastic
Coulomb scattering from nuclei. Due to the large mass of the nuclei com-
pared to the incoming particle, the energy transfer is negligible, however the
direction of the particle can alter. This results in divergence of the beam.
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Figure 2.4: The stopping power − dE
dX
in different materials [14].
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Figure 2.5: FLUKA Monte Carlo simulation. Dose deposition from 3 proton
pencil beams with the energies; 80 MeV, 110 MeV and 150 MeV.
Figure 2.6: FLUKA Monte Carlo simulation. The 2D projection of dose de-
position in water from a 150 MeV proton pencil beam.
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Figure 2.7: FLUKA Monte Carlo simulation. Proton fluence from a 130 MeV
pencil beam in water. The unit for the fluence in FLUKA is particles pr area
(cm2) pr primary particle [16].
Nuclear Reactions
Charged particles can interact with matter via nuclear reactions. This is
rare, and can be neglected when the initial kinetic energy is lower than the
Coulomb barrier.
Fluence
The fluence, Φ , is defined as the number of particles crossing an infinitesimal
element of area dA normal to z (beam direction).
Φ =
dN
dA
(2.5)
For a beam of protons, the fluence of primary protons is very consistent
towards the Bragg peak. The reduction of proton fluence is about 1-2 % per
cm in water, as illustrated in figure 2.7 [15].
2.3 Radiation Biology
Radiation biology is invoked when quantifying the relationship between a
physical absorbed dose in the tissue, and the resulting effect. There is yet
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not enough systematic data for a comprehensive description of the dose re-
sponse relationship for human beings, hence no unambiguous limit of dose
tolerance is known, but experiments on animals and records of dose exposure
and casualties in historical events, such as the atomic bombs in Japan 1945,
have displayed a range of doses during which the risk of damage increases
from 0 % to 100 % as a function of increasing dose. A diagram displaying
the effect of irradiation as a function of dose is commonly known as the dose-
response curve.
The clinical most important impact of radiation is caused by ionization. It is
the ability of ionization of the medium traversed that makes the particles at-
tractive for treatment of cancer, since the ionization can cause damage to the
DNA molecules in a cell. Radiation causes damage to the DNA by breaking
one or both molecular strands. Cells are regarded as killed when they have
lost their reproductive ability.
2.3.1 Linear Energy Transfer (LET)
The linear energy transfer (LET) is defined as the energy transferred to the
absorbing medium per unit track length of the particle. LET is usually given
in units of keV/µm. Therapeutic photons are regarded as low-LET particles,
with an LET value of about 0.2 keV/µm, while 2.5 MeV α particles have an
LET value of 166 keV/µm and are categorized as high-LET particles. A 150
MeV proton have an LET value of about 0.5, and are considered among the
low-LET particles [17].
2.3.2 Relative Biological Effectiveness
There is a difference in what biological effect a certain dose provided by
different particles will have. The Relative Biological Effectiveness (RBE) is
given by the ratio of the dose of a reference radiation and the dose of the
applied radiation to give equal biological effect. Historically 250 kV X-rays
are regarded as the standard reference radiation which to normalize the effect
other types of particles will have.
RBE =
Dose of 250 kV X rays
Dose of test radiation
(2.6)
In clinical proton therapy an RBE value of 1.1 is used. This is mainly based
on experiments with animals conducted in the early days of proton therapy.
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Figure 2.8: The dependence of Relative Biological Effectiveness (RBE) on
linear energy transfer (LET). SF is an abbreviation of survival fraction [20].
The RBE is not a constant, rather it depends on various properties such as
proton beam energy, depth in tissue and dose per fraction [15]. Studies have
shown that the proton RBE can deviate from the value of 1.1, and that this
generic value is more of an average value [18].
The RBE depends on the LET and increases with increasing LET until it
reaches a maximum around 100 keV/µm, and declines above this value. To
ensure that a cancer cell is killed, a sufficient amount of energy must be de-
posited in the cell in order to destroy the DNA molecule. Low-LET particles
are sparsely ionizing and many particles are needed to kill a cell. Very high-
LET particles with LET higher than 100 keV/µm are densely ionizing and
deposit even more energy in the DNA than what is required in order to kill
the cell [19]. This effect is illustrated in figure 2.8.
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2.3.3 Dose
The term absorbed dose is defined as the amount of energy (Joule) absorbed
per unit of mass (kg). The definition is that 1 Joule/kg corresponds to the
S.I. unit of 1 Gray (Gy). The energy lost by the protons exceeds the energy
absorbed by the medium. The reason for this discrepancy is that some of the
protons lose energy by the production of neutral secondary particles, such as
photons and neutrons, that can carry the energy away from their origin and
deposit it elsewhere outside the volume of interest [15].
Since different types of radiation have different effects on matter, one needs
to take into account various factors to predict the effect of a given radiation
dose. In order to be able to compare the biological effectiveness of different
types of radiation in tissue, the term equivalent dose has been established.
The equivalent dose HT is the product of the absorbed dose DT and the ra-
diation weighting factor WR. The S.I. unit for equivalent dose is Sievert (Sv)
[17]. Table 2.1 displays the weighting factors for different types of radiation.
HT =
∑
WRDT (2.7)
Table 2.1: Quality factor WR for different types of radiation [21].
Type of radiation Energy Quality factor
Photons, electrons all energies 1
Neutrons < 10 keV 5
10 - 100 keV 10
100 keV - 2 MeV 20
2 - 20 MeV 10
> 20 MeV 5
Protons < 20 MeV 5
Alfa particles,
fission fragments,
heavy nuclei 20
Different organs and tissue in the body have different sensitivities for
radiation. To estimate the risk of damage caused by radiation in humans, the
entity effective dose is more describing. In the term effective dose a tissue-
specific weighting factor, WT is added. The unit of effective dose is Sievert.
Table 2.2 summarize tissue-specific weighting factors for organs.
The differences in radiation tolerance within the human body is something
that has to be considered when making a treatment plan for a patient. Some
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Table 2.2: Tissue-specific weighting factorsWT given by ICRP (International
Comission on Radiation Protection).
Organ/tissue WT ICRP (2007) WT ICRP (1991)
Breast 0.12 0.05
Bone marrow 0.12 0.12
Colon 0.12 0.12
Lung 0.12 0.12
Remainder 0.12 0.05
Stomach 0.12 0.12
Gonads 0.08 0.20
Bladder 0.04 0.05
Liver 0.04 0.05
Oesophagus 0.04 0.05
Thyroid 0.04 0.05
Bone surfaces 0.01 0.01
Brain 0.01 -
Salivary glands 0.01 -
Skin 0.01 0.01
organs are considered "serial", such as the spinal cord. A damage to one part
of the spinal cord can be fatal for the whole organ. In the clinical regime,
serial organs have to be treated with special care to avoid over dosage. At
the same time some organs are considered "parallel" such as liver or lung.
Parallel organs can operate even if one part of it is damaged. Knowledge of
the dose delivered to a critical organ, and the uncertainties that need to be
considered, is important when making decisions about treatment.
Stopping Power
In particle therapy the term stopping power has its use. Stopping power is
the rate at which a single proton loses kinetic energy:
S = −dE
dx
MeV
cm
(2.8)
The mass stopping power is corrected for density:
S
ρ
= −1
ρ
dE
dx
MeV
g/cm2
(2.9)
The physical absorbed dose is related to the mass stopping power and the
fluence:
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D = Φ
S
ρ
(2.10)
The dose rate is given by the relation:
D˙ =
ip
A
S
ρ
Gy
s
(2.11)
where ip/A is the proton current density in nA/cm2. A high dose rate is a goal
for the development of treatment techniques. Reducing the overall treatment
time reduces the uncertainties related to patient movement [15].
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Chapter 3
Radiation Therapy
About half of all cancer patients receive radiation therapy [2]. Radiation
treatment can be given in combination with chemotherapy or surgery, or
both. Treatment techniques have evolved radically during the last decades,
alongside the increased availability and quality in medical imaging and com-
puting power.
3.1 Medical Imaging
Medical imaging has been one of the key factors enabling precise treatment
in many fields within medical science. Efforts have been successfully made
to reduce noise, increase resolution, reduce imaging time and also to reduce
exposure to ionizing radiation.
3.1.1 Computed Tomography (CT)
Within diagnostic imaging prior to radiation therapy, Computed Tomogra-
phy (CT) is the imaging modality most commonly used. In short, a CT
scanner consists of a rotating X-ray tube that produces bremsstrahlung, and
an array of detectors that can detect and read out the signals. With the use
of X-rays, a 3D image of the body is created, slice by slice. Figure 3.1 illus-
trates the principle of CT. A CT examination maps the various attenuation
coefficients throughout the body. The attenuation of a photon beam in a
given tissue is presented in a scale which is normalized with respect to the
attenuation of photons in water, and this is displayed in a normalized (grey)
scale, this scale is the Hounsfield Unit (HU) scale, and the HU is defined as;
HU = 1000× µtissue − µwater
µwater
(3.1)
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Figure 3.1: The principles for Computed Tomography. An X-ray tube revolves
around the patient, and a detector array detects the attenuated X-rays on
the other side of the patient. The signals from the detectors are read out and
based on the information about the attenuation in the body, a map of body
is made. This is repeated slice by slice through the patient [22].
The HU for water is set to 0, for air it is -1000 and for bone and denser
materials it is +1000 and upwards. The HU range from -1000 to about +3000
in human body tissue. Metal implants can have a HU of up to around +5000.
Imaging with Computed Tomography (CT) is a well established image
modality. Most hospitals are in possession of a CT scanner. A CT examina-
tion performed in one clinic should be possible to interpret in another clinic.
CT is a versatile tool and it provides a detailed anatomical presentation of
the body. In CT images there will be a sharp contrast between bone and tis-
sue. A CT scan can be conducted during one breath hold cycle, if necessary
or desired. When a patient has undergone a diagnostic CT scan, the images
will be examined by radiologists and oncologists. Thereafter the CT image
set is imported to a treatment planning software, and a plan for the radia-
tion therapy prescription will be created. In the treatment planning software
an oncologist will delineate the volume(s) to be treated and critical organs
around the tumour and thereby creating the Clinical Target Volume(s) and
Organs At Risk (OAR).
There are some limitations when using CT images, which displays tissue
density, as the basis for tumour delineation. The exact locations of where
healthy tissue ends and tumour tissue starts can be hard to identify based
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on CT images without additional diagnostic information. The density of tu-
mour tissue may be almost identical to that of nearby healthy tissue or of
organs at risk close to the tumour. Further, the CT images can be noisy and
contain artefacts, this is more frequent when a patient has a metal implant.
For particle therapy these uncertainties can alter the dose calculation. The
conversion from Hounsfield Units to proton stopping power can be a source
of uncertainties. This topic is further addressed in section 3.5. Sharp density
gradients can cause a problem since the CT images has a finite resolution and
small objects and sharp gradients may be influenced by the partial volume
effect. Since the photon depth dose profile does not possess the sharp distal
dose gradient characteristic for charged particles, these uncertainties do not
have the same impact in photon therapy as in particle therapy.
DICOM DICOM is a standard for handling, storing, printing and trans-
mitting information in medical imaging. DICOM is an abbreviation from
Digital Imaging and Communication in Medicine. Both CT-,MR- and PET-
CT images are stored in DICOM format files and the information can be
exchanged between two clinical treatment units or hospitals provided they
all apply the DICOM standard.
3.1.2 Positron Emission Tomography (PET)
Positron Emission Tomography (PET) is an image modality where the pho-
tons detected in the scanner originate from the body, as a result of positron
emission. The most common PET scan in oncology involves injection of the
radioactive tracer fluorodeoxyglucose (18F -FDG) into the bloodstream of the
patient in order to obtain images displaying the uptake of this radiopharma-
ceutical in the patients body. The metabolic processes in the human cells use
glucose as a source of energy. Since cell-division in tumours demand a lot of
energy, they will take up 18F -FDG. The 18F is a radioactive isotope with a
half-life of around 110 minutes. 18F decays to 18O via positron emission. As
the positron annihilates with an electron, two gamma photons will be emit-
ted back-to-back and these will be detected by the PET camera based upon
coincidence criteria. Most PET scanners in use on hospitals has a combined
PET-CT scanner system where the PET image is fused into the CT image
in order to obtain PET and CT information in the same images.
PET can also be useful for tracing the deposited dose in particle therapy.
As mentioned in chapter 2, there will be production of radioisotopes such as
11C, 13N and 15O in a patient’s body during particle therapy. This will lead
to positron emission in the tissue traversed, and this positron emission can
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Figure 3.2: An example of application of a PET signal as a measure of dose
deposition; Measured positron activity (solid line) and dose (dashed line)
as result of protons (left) and 12C ions (right) hitting a PMMA target. For
the 12C ions there is a peak activation shortly before the Bragg peak (right
image), while for proton beam activation, the activation is a result of target
fragmentation along the beam path (left image). From Parodi, PhD thesis
[23].
be mapped with a PET camera. Dose imaging by this method must be car-
ried out either during the treatment, or within some minutes after treatment.
By using this method, the actual dose distribution in the patient can be de-
duced, and this can be compared with the predicted dose from the treatment
plan. The unavoidable activation of the patient can thus be utilized without
invasion or additional dose to the patient as a measure of dose deposition in
the patient’s body.
In figure 3.2 the β+ activation for proton beams and 12C ion beams are
shown. Protons can only produce positron emission from target nuclei in the
media traversed. The isotopes (such as 11C, 15O and 13N) are formed along
the beam path, until a few millimeters in front of the Bragg peak. For heavier
ions, such as 12C, positron-emitting projectile fragments are also produced.
This activation will happen shortly before the dose Bragg peak [15] [23].
3.2 The Therapeutic Ratio
The term "the therapeutic ratio" is referred to as an outcome assessment of
the treatment in radiation therapy. The therapeutic ratio is the ratio of the
probability for tumour eradication and normal tissue complication and these
entities are modelled and represented in so-called dose-response curves. The
efforts made to improve delivery techniques and treatment modalities focus
mostly on improving the therapeutic ratio and hence broaden the "therapeu-
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Figure 3.3: Sigmoid dose-response curves. The therapeutic ratio is the ratio
between the probability for local tumour control and normal tissue compli-
cation [24].
tic window" [15]. The dose-response curve has a sigmoid shape, as illustrated
in figure 3.3.
3.3 Fractionation
A radiation treatment course is split into fractions. The reason for this is
that the healthy tissue needs some time to repair after being irradiated. The
tumour cells can also repair their damage, but their ability is inferior com-
pared to healthy cells, and as the treatment course continues, the cancer cells
are gradually inactivated and thus put out of reproductive action. A typical
treatment course can for instance consist of delivery of a prescribed dose of
50 Gy delivered in 25 fractions of 2 Gy each. The total dose and fractionation
scheme depends on the diagnosis and whether the treatment is curative or
palliative.
The fractionation scheme applied in proton therapy differs little from the
fractionation scheme applied for a corresponding treatment with photons. A
proton beam will have a ∼10 % higher biological effectiveness compared to
photons, this enhanced RBE has not yet motivated a very different fractiona-
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tion regime for proton therapy compared to photon therapy. For heavier ions
such as 12C-ions, the RBE will be higher (ranging from 2 to 3) and thus a
more effective tumour eradication is invoked. Hence, the prescribed dose can
be delivered in fewer fractions. At the 12C-ion treatment facility HIMAC,
operated by the Japanese National Institute for Radiological Science, NIRS
in Chiba, Japan, patients have been treated with as few as one fraction [25].
3.4 Radiation Therapy with Photons
Radiation therapy with photons are considered the standard radiation treat-
ment of cancer worldwide. The field has undergone a tremendous develop-
ment since the early days of radiation therapy, more than a hundred years
ago. Medical linear accelerators are being used to provide photon beams with
energies ranging from a few MV to about 20 MV.
3.4.1 The Medical Linear Accelerator
The medical linear accelerator (linac) uses high-frequency electromagnetic
waves to accelerate electrons towards a target. The electromagnetic wave
can be travelling or stationary, depending on the design. When the elec-
trons strike the target, usually made of a high-Z material, such as tungsten,
bremsstrahlung X-rays will be produced. It is also possible to remove the
target and utilize the energetic electrons in treatment of superficial lesions.
The energy of the X-rays are spectrum distributed with the maximum energy
equal to the acceleration gap electron energy, given in units of MV (mega
volts). The radiation field will be shaped for the treatment fields to cover the
tumour volume with some margins. The field shaping is done in the treatment
head with collimators, scatter foils and filters. Figure 3.4 shows a schematic
view of the treatment head of a typical medical linac.
3.4.2 Treatment Techniques
Various treatment techniques have been developed alongside the develop-
ment of better imaging equipment and also with vastly improved computing
power. When a more accurate and detailed patient anatomy is available for
the oncologists, this enhances the possibilities for them to improve the tar-
get definitions and for them to delineate the target volumes more precisely.
This induces in turn the possibility and a need for a more targeted treatment
and treatment delivery. Based on the geometry provided by 3D CT images,
a dose plan is created, in which all the details about the treatment, such
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Figure 3.4: The major components in a typical linear accelerator treatment
head. In image A: photon therapy mode. The first collimation is done by the
fixed primary collimator. The beam passes through a flattening filter in order
to create a homogeneous field of photons. The dose rate and field symmetry
are monitored in the dose monitoring chambers located above the adjustable
secondary collimators. In image B: electron therapy mode [11].
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as treatment dose, dose distribution, treatment machine, treatment energy,
beam angles, collimator angles, patient position etc, are described.
In order to reduce the uncertainties during radiation treatment as much as
possible, patient immobilization is a fundamental factor to be dealt with.
The immobilization revolves around how to fixate the patient to the treat-
ment position with masks and other equipment tight enough for helping the
patient to remain fixated but comfortable enough for the patient to lay still
during irradiation. Frequently used are; headmasks, upper body masks, spe-
cial fixation mattresses, knee fixation pillows and bite blocks moulded to fit
the patient’s jaw. The tumour can move inside the body, this is especially
important to handle for cases with tumours in the thorax or abdomen. To
take into account these unavoidable and involuntary movements, the target
volume needs a margin, thus the clinical target volume must have margins so
that the irradiation will cover the tumour at all times during the treatment,
these margins added to the clinical target volume produces a larger volume
covering the clinical target volume, the planning target volume. In order to
spare healthy tissue, one wishes and tries to reduce these margins as much
as possible. A robust treatment plan is characterized by the ability to main-
tain a satisfactory dose coverage of the target volume, despite changes in the
geometry.
3D Conformal Radiation Therapy
With the 3D anatomic information from a planning CT scan, the tumour
will be delineated in all dimensions. With 3D conformal radiation therapy,
the beams will be shaped and designed to fit the target shape and position.
To cover the target volume and at the same time spare surrounding tissue,
the number of beams, the beam angles, the beam intensity and beam shape
will be determined using a treatment planning program. Hardware such as
collimators are used to obtain the desired beam shape and properties.
Intensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy utilizes the initial non-uniform beam
if the treatment machine is Flattening Filter Free (FFF) as recent linacs now
can bee, otherwise the IMRT will be delivered from the flattened radiation
fields. The target volume is irradiated from multiple directions around the
patient. The intensity and shape of the beam is adjusted step-by-step to fit
to the target shape. IMRT relies on advanced computer algorithms. The user
will set a list of criteria, such as desired dose to the target volume, max dose
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to the surrounding tissue and organs at risk, and also a relative priority,
by weights, for each of these criteria. The treatment planning program will
then optimize the radiation intensity with a set of (user specified) beam
directions to meet these criteria, thus this technique is called inverse planning.
Especially for tumours with a challenging shape, IMRT will in general be able
to provide a better tumour dose coverage than conformal techniques, while
at the same time keep the dose to surrounding tissue low [26].
Volumetric-Modulated Arc Therapy (VMAT)
With Volumetric-modulated Arc Therapy, VMAT, the concept from IMRT
and using multiple beam directions is further utilized. With VMAT the
gantry delivers photon radiation continuously while rotating around the pa-
tient. The beam is continuously modified by both multileaf collimators and
gantry movement to cover the target volume structure, and to spare healthy
tissue [27].
3.5 Particle Therapy
Particle therapy is also referred to as hadron therapy or ion therapy; regard-
less of the name, it all refer to use of charged nuclear particles in radiation
therapy. The particles used are protons (hydrogen ions), helium ions, lithium
ions, oxygen ions, neon ions and carbon ions, of which protons are the far
most common particle used followed by carbon ions as of 2013. When ap-
plying charged nuclear particles, given their characteristic depth dose distri-
bution one enables delivery of higher doses to the tumour while maintaining
the total dose to surrounding structures, and even reducing the total dose to
these structures. By deposition of the nuclear particle’s Bragg Peak in the
target volume area, the maximum dose deposition will be in the tumour itself
and hence the therapeutic ratio will increase, and thus this will potentially
increase local control, decrease occurrence of side-effects and improve quality
of life of the patient [15]. In figure 3.5 a cubic volume of water, placed inside
a larger water phantom is treated with a) protons and b) photons, both with
one treatment field. A clinical case is shown in figure 3.6, where a patient
geometry is subject to a proton treatment plan and a photon treatment plan.
The patient is a child with medulloblastoma cancer, a condition for which
a part of the treatment includes irradiation of the entire spinal cord axis.
One can see that in the photon plan, the whole upper body gets unwanted
and unavoidable dose. This includes critical organs such as the heart, lungs,
intestines and the oesophagus. In figure 3.7 the photon and proton depth
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dose profiles in water are plotted together. The photon beam will have its
dose maximum a couple of cm into the water volume, and then the dose
deposition decreases with depth.
To estimate the stopping power in a patient is a key point when making
decisions about treatment. This issue will be addressed further in section 3.6.
The range of the proton depends on the energy of the proton beam. Figure
3.8 shows the range in water as a function of initial energy. In proton therapy
the energies for therapeutic use is roughly 50 MeV - 250 MeV. The theoretical
range in units of g/cm2 in a homogeneous material is given by equation 3.2.
R (Einitial) =
∫ Efinal
Einitial
(
1
ρ
dE
dx
)−1
dE =
∫ Einitial
Efinal
dE
S/ρ
(3.2)
This relation between range and energy can be fitted to a simple equation,
the Bragg-Kleeman rule. The range of a proton beam is defined to be the
position in depth of the distal 80 % (d80) dose level of the Bragg peak [15].
R = αEp0 (3.3)
Where α = 0.0022 cm/MeV and p0 = 1.77.
If a beam of protons with the exact same initial energy enters a material,
they will not stop at the exact same depth. This is due to the statistical
nature of the interactions each proton undergo. This leads to what is known
as range straggling. The range straggling is about σRS= 1.2 % of the range
for light materials. A realistic proton beam will have a small energy spread
σbeam [15]. Straggling makes the Bragg peak broaden. The width between the
position in depth of the distal 80 % dose level, d80, and the position in depth
of the distal 20 % dose level, d20, of the Bragg peak will depend on these two
properties:
d20 − d80 = 1.3×
√
σ2RS + σ
2
beam (3.4)
The transversal distribution of a proton beam is nearly Gaussian. This
smearing out of the distribution of beam particles is a result of multiple
Coulomb scattering, many tiny angular deflections. The multiple Coulomb
scattering occurring in the patient sets the lower limit for the resolution of
the treatment.
The lateral penumbra of a proton beam limits the accuracy, or the resolu-
tion, of the treatment. This effect is less pronounced when applying heavier
charged particles such as helium, and the effect is even smaller for carbon
ions, as illustrated by figure 3.9.
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(a) The target volume irradiated with protons.
(b) The target volume irradiated with photons.
Figure 3.5: The calculated dose to a volume irradiated with a) protons and
b) photons, both with one treatment beam. One can see that the photons
has a dose maximum located a couple of cm into the phantom. The target
volume is 5× 5× 5 cm3 and is located in the center of a water phantom. The
software used for this calculation is Varian Eclipse Proton Planning.
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(a) The target volume irradiated with protons.
(b) The target volume irradiated with photons.
Figure 3.6: Treatment plans made with a) proton therapy and b) photon
therapy, both plans are calculated with Varian Eclipse software. The patient
is a child with medulloblastoma, a condition that occurs more often for chil-
dren than for adults. Part of the treatment involves irradiation of the entire
spinal axis. These treatment plans are part of ongoing doctoral work [28].
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Figure 3.7: FLUKA Monte Carlo simulations. Depth dose profile plotted for
15 MV photons, 150 MeV protons and a spread-out Bragg peak with proton
beam energies from 116 MeV to 146 MeV in water. Photon beam data used
with permission from [29].
Figure 3.8: The proton range in water as a function of initial energy [15].
33
Figure 3.9: The lateral penumbra of photons, protons and carbon ions in
water [30].
3.5.1 Particle Accelerators
In order to deliver particles with the sufficient energy for therapeutic use,
a particle accelerator is needed. During the first decades after the introduc-
tion of particle therapy, patient treatment were conducted at nuclear physics
laboratories equipped with a particle accelerator, usually a cyclotron or a
synchrocyclotron. Once the treatment with protons had proved to be feasi-
ble, dedicated treatment facilities started to emerge. For a proton treatment
unit to fit within limited spacing such as hospitals and clinics, especially in
urban cites, efforts are being made to develop compact accelerator systems.
Still the particle sources are quite space consuming, not only the accelerator
itself, but also the radiation shielding (walls) and beam line hardware (mag-
nets) [15].
There are two main accelerator types in use today: cyclotrons and syn-
chrotrons.
Cyclotron
In a cyclotron there is an ion source located in the centre. The ions are pulled
out of the ion source, and pushed into a vacuum chamber. The particles are
accelerated by a radio frequency (RF) system and their trajectories are bent
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and confined by a strong magnetic field. The ions will follow a spiral shaped
orbit, allowing repeated acceleration by the RF-voltage. As their velocity
increases, their radius increases until the desired energy is reached and an
extraction system will maneuver the ions out of the cyclotron and into the
beamline [15]. The electrical nodes giving rise to the electric field in the accel-
erating gap are historically called "dees" for their resemblance to the letter,
as can be seen in figure 3.10 [31].
The Lorentz force acts as the centripetal force, giving us the relation:
Bqv =
mv2
r
(3.5)
Bq =
p
r
(3.6)
v =
2pir
T
(3.7)
T =
2pim
qB
(3.8)
The radio-frequency of the accelerating system is synchronized to the
path of the particle, and it is given by the cyclotron equation:
ω =
qB
m
(3.9)
Synchrocyclotrons will adjust their RF frequency to compensate for the
relativistic change in the particle mass as their velocity increase. The Lorentz
factor γ increase with v:
γ =
1√
1− v2
c2
=
1√
1− β2 (3.10)
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Figure 3.10: Schematic drawing of a cyclotron.
The particle beam from an isochronous cyclotron will have a continu-
ous character while the particle beam from a synchrocyclotron will have a
pulsed character. For both types the intensity is easily adjusted to almost
any desired intensity within the accelerator specifications. The beam energy
is fixed at the maximum energy of the accelerator. The cyclotrons used in
proton therapy have a diameter of 3.5 - 5 m depending whether or not they
are equipped with superconducting magnets.
Currently cyclotrons are only in use for proton therapy, not for heavier par-
ticles such as carbon ions.
Synchrotron
In a synchrotron the radius is fixed while the magnetic field is adjusted as
the particles are being accelerated. The particles need some initial kinetic
energy before they enter the synchrotron ring. This is typically provided by
a linear accelerator, providing the particles with an energy of 3 to 7 MeV.
For each time the particles have been pushed forward by the accelerating
RF cavity, the magnetic field provided by the focusing and bending magnets
along the ring must increase. Figure 3.11 shows a simple schematic drawing
of a synchrotron. Figure 3.12 is a photograph displaying the synchrotron at
CNAO in Pavia, Italy. At CNAO patients are treated both with protons and
carbon ions [32].
The protons are accelerated to the desired energy between 70 and 250
MeV, and then extracted. In this way, the beam energy can be modulated
during operation. The beam does not have the continuous nature of the
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Figure 3.11: Schematic drawing of a synchrotron [31].
Figure 3.12: The synchrotron at the hadron therapy facility CNAO in Pavia,
Italy. At CNAO the synchrotron accelerates both protons and carbon ions.
Photograph by the author, March 2013.
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isochronus cyclotron beam. The particles come in pulsed "spills", and the
energy can be adjusted between the spills.
For heavy ion therapy, synchrotrons are currently the only option for parti-
cle acceleration. The diameter of synchrotrons in therapeutic use are 6 - 25
meters, depending on the type of particle produced. The energies applied in
heavy ion therapy range up to about 400 MeV pr nucleon, which corresponds
to a range of 25 cm i water [31].
3.5.2 Energy Modulation - Creating a Spread Out Bragg
Peak
The proton beam from an accelerator will be almost monoenergetic and ex-
hibit a narrow Bragg peak. To cover the target volume in its full depth, the
beam energy has to be adjusted in order to create a so-called spread-out
Bragg peak (SOBP). Beams of different ranges are added either by alter-
ing the initial energy from the accelerator, either by adding material in the
beam line, or by directly adjusting the beam energy in the accelerator (only
possible with synchrotrons).
To produce an SOBP with a flat dose plateau at the desired depth and
with a given thickness, each energy interval needs to be weighted relative
to the other intervals. The highest energy, which constitutes the distal edge
of the SOBP, is attributed the highest weight. In figure 3.13 two plots are
shown. In figure 3.13 a) 21 beam energies are plotted in the same diagram,
unweighted. In figure 3.13 b) all the beams are weighted in order to obtain
an SOBP when the beams are added.
Range Modulator Wheel Many facilities use a range modulator wheel
(figure 3.14) to create the correct spread in energy. There are many designs
available, but the basic idea is the same. The radius of the wheel is constant,
while the thickness is distributed in a steplike fashion, where the area of each
step reflects the weight of the corresponding energy, or range.
Ridge Filter The principle behind the ridge filter (figure 3.15) is the same
as for the range modulator wheel mentioned above. However, the ridge filter
is a static component positioned in the beamline. The beam is spread to a
monoenergetic, homogeneous field of protons before entering the ridge filter.
The shape of each of the ridges determines the shape of the SOBP. Ridge
filters are commonly used in carbon therapy facilities, but are also used for
protons.
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(a) The longitudinal depth dose profile from the 21 beams with energies ranging
from about 116 MeV to 146 MeV. In this plot all beams have the same weight.
(b) The longitudinal depth dose 21 beams are weighted and added to create an
SOBP.
Figure 3.13: FLUKA Monte Carlo simulations. The principle behind the
spread-out Bragg peak. Beams of different energies are added in a certain
way to obtain a flat dose plateau at the desired depth.
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Figure 3.14: Photograph of a typical range modulator wheel. The wheel will
rotate in the beamline, making the beam traverse different thickness of ma-
terial at each step in the wheel [33].
Figure 3.15: Photograph of a ridge filter. The beam is spread twice before
entering the ridge filter. The height and width of the ridges determines the
shape of the SOBP. An additional range shifter can be used to position the
SOBP at the desired depth [15].
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Figure 3.16: Photograph of a range shifter wedge. The wedges are pro-
grammed to be positioned in the beam to create the desired dose profile
[34].
Lamination A slightly more sophisticated way of modulating the range of
the beam is by the method called lamination. Instead of applying prefabri-
cated hardware, designed for each thickness or shape, the range modulation
can be achieved by placing material in the beam in a programmed way. Thin
layers of lead and plastic, wedges (figure 3.16) or an adjustable water column
can be controlled by a computer to apply a certain thickness in the beam.
Choice of Material in Energy Modulators The materials used in en-
ergy modulation has to be carefully chosen. Once the beam enters a range
modulator, further scattering of the beam is not desired. Hence, a low-Z
material such as aluminium, carbon or even plastic is usually applied in
range shifter wheels and ridge filters. The lateral spread of the beam cam be
accomplished by the use of scatter foils in the beam line. For scatter foils a
combination of high-Z (such as lead) and low-Z materials are usually applied.
Proton Nozzle A schematic layout of how a proton treatment head, a
proton nozzle, can be constructed is shown in figure 3.17.
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Figure 3.17: Schematic layout of a proton nozzle, from Varian’s Eclipse Pro-
ton Planning reference guide [35].
3.5.3 Treatment Techniques
The treatment techniques used in proton therapy can be split into two main
categories: the scattering technique and the scanning technique. The basic
principles are illustrated in figure 3.18.
Scattering The scattering technique was the first technique used to modu-
late the proton beam to achieve the desired coverage of the treatment volume.
It was developed during the 1960’s and it is still a widespread technique. In
a scattered beam system, the narrow beam from the accelerator is scattered
to a larger area, to become a field, with a uniform intensity. To create a
spread-out Bragg peak that covers the depth of the target volume, a range
shifter wheel or ridge filter is used. To fit the structure of the treatment vol-
ume, a collimator, usually made of brass, is used to shape the field, while
a compensator, usually made of plexi glas, is placed in the beam to make
the maximum range of the protons follow the distal end of the tumour. The
collimator and the compensator are field-specific and has to be produced for
each patient (each tumour and each field).
Scanning The scanning technique is an active way of covering the target
volume. By utilizing the narrow pencil beam obtained in the accelerator,
varying magnetic fields will bend the beam and close to the patient steering
magnets will enable a precise lateral scan through the each energy layer of
the target volume. To distribute the dose deposition in order to cover the
target volume in the longitudinal direction, in depth, the energy of the beam
is modulated. The energy can be modulated using a range modulator such as
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(a) The scattering technique beam delivery.
(b) The scanning technique beam delivery.
Figure 3.18: The principles behind the two main categories of treatment
techniques, a) scattering [29] and b) scanning, [36].
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a lamination system. Or if the accelerator is a synchrotron, the energy from
the accelerator can be adjusted.
The scanning technique is a relatively new treatment method and it is devel-
oping rapidly as more and more clinics start using it. It has many advantages
over the scattering technique. With the scattering technique there is exten-
sive use of hardware such as collimators and compensator that has to be
uniquely designed and manufactured for each patient and even each field
direction. The generation of secondary particles such as neutrons is also re-
duced when using the active scanning approach. With a scanned beam there
are multiple degrees of freedom and based on the experience from dose calcu-
lation and dose planning with photons, advanced techniques such as IMPT
has emerged.
Uniform Scanning The uniform scanning technique uses a fixed scanned
beam, and field shaping devices to cover the target volume. Constant beam
intensities that are adjusted relative to the others are used to produce a flat
dose plateau along the beam direction. As with the scattering technique,
beam collimators and range compensators are used to fit the dose to the
tumour. The production of secondary particles in the beam shaping aperture
is still less than what is the case for scattered beams. This is due to the fact
that for uniform scanning beams, the lateral width of the beam is adjusted
to fit the collimators. The overall dose distribution in uniform scanning is
more or less the same as for the scattering technique [15] (p. 108).
Single-field Uniform Dose (SFUD) With the SFUD technique the
beam intensities and scanning pattern is customized for the field. The dose
distribution for each field is uniform over the treatment volume [15] (p. 108).
To make a more robust treatment plan, one can apply the SFUD technique
on multiple fields, yet the fields are independent of each other.
Multifield Uniform dose (MFUD) Multifield uniform dose, or In-
tensity Modulated Proton Therapy (IMPT) is an active scanning technique
analogous to intensity modulated radiation therapy (IMRT). With this tech-
nique the uniform dose coverage of the treatment volume is obtained as the
resulting dose from two or more fields. With both MFUD and SFUD the
SOBP is no longer the same concept as for uniform scanning or scattering.
The treatment plan will assign an array of Bragg peaks, each calculated to
hit one spot in the target volume. This way the volume will be irradiated
spot by spot, layer by layer.
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3.6 Range Uncertainties
As in photon therapy there are a number of uncertainties in proton therapy
that one needs to be aware of. Setup errors, patient motion, physiological
changes and stopping power estimation errors are all factors that can alter
the precision of the treatment. Uncertainties in the proton range related to
tissue heterogeneities and the estimated stopping power in the patient must
be considered in order to deliver clinically adequate proton therapy. A com-
mon property used in proton therapy is the water equivalent path length
(WEPL). The proton range depends heavily on the conditions leading to the
WEPL along the beam path. If the material contents in the planned beam
path changes during treatment, and thus the WEPL changes by a certain
amount, the distal dose falloff will change correspondingly. This can lead to
unwanted under dosage of the target volume and over dosage to the sur-
rounding tissue, both compromising the quality of the treatment. Due to the
depth dose characteristics of photons, a similar change in WEPL will not
have the same impact on the delivered dose with photon therapy [15] [14].
Predicting the proton beam behaviour in a homogeneous water phantom of
is straightforward. However, predicting the proton behaviour in a dynamic
human body can be challenging. Inhomogeneities such as bone of varying
size and density, gas or even medical implants can have large effects on the
proton range. In addition there can be movement related to the respiratory
cycle, heartbeats, digestion and other voluntary or involuntary movements.
From Hounsfield Units to Stopping Power Conversion The range
of the proton beam, and thus the energy required to direct the Bragg peak
at the target, is calculated based on the CT images. As mentioned above,
CT Hounsfield Units are derived from the attenuation of X-rays. The proton
stopping power depends on the physical density, elemental composition and
mean ionization energy of the absorbing material. The CT HU numbers are
converted to proton stopping power using a calibration curve. The method
used to obtain this curve is called the stoichiometric method. Stoichiometry
refers to the description of the quantitative relationship among substances
in for instance a compound involved in a reaction. For a number of human
tissues, the HU value is measured with X-ray CT, as well as calculated based
on knowledge of the material. The theoretical proton stopping power is calcu-
lated based on the material’s known elemental composition and the material
properties, using a simplified version of the Bethe-Bloch equation [15]. The
HU values are plotted against the relative proton stopping power, and a curve
is fitted to this plot. The resulting fit is commonly a combination of three
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linear fits; the first curve fits the lung data, the second fits the various organs
and the last fits the bone tissues [37]. The stoichiometric approach was pro-
posed by Pedroni, Schneider and Lomax in 1996 [37]. Figure 3.19 displays the
CT calibration curve implemented in the Eclipse Proton Planning software.
Figure 3.19: The CT value conversion curve from Varian Eclipse. Based on
the stoichiometric method a CT calibration curve is obtained. In this plot the
x-axis represents the HU values and the y-axis represent the relative proton
stopping power.
Although the stoichiometric method provides a good estimate of the stop-
ping power, it is important to note that the HU and the proton stopping
power result from different physical processes and there is no clear-cut one-
to-one relation between the two [38].
Proton Imaging
The systematic error of the conversion between the HU value and the proton
stopping power is typically in the order of a few % [39] [15]. X-ray CT is like
any other imaging modality prone to artefacts, in particular for imaging sites
with metal implants such as dental fillings and medical prostheses.
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To address this uncertainty one solution proposed is the use of proton CT.
With a proton CT the proton beam is used to create an image of the pa-
tient. For proton CT the beam energy must be high enough for the protons
to come to rest and deposit their Bragg peak beyond the patient, not in-
side the patient, along the beam axis. This energy is needed because proton
CT is based upon the principle that the Bragg peak will be deposited in
the detector behind the patient, and not in the patient, and with knowledge
about the incoming proton beam energy and the distribution of the Bragg
Peak position, one will obtain knowledge about the deposited energy in the
patient and hence be able to deduce the stopping power of the patient tissue.
Depending on what part of the body that is to be treated a maximum energy
of more than 300 MeV is required from the accelerator.
Application of a Proton CT will give direct information regarding the proton
behavior, in particular the range, in tissue, and it can potentially be less
prone to artefacts due to high-Z materials [40]. In addition to this, the dose
given to the patient during proton CT imaging can potentially be lower than
for traditional X-ray CT with the same density resolution [41]. Using the
treatment beam for imaging reduces the number of devices that otherwise
would have to be in the treatment room. Most clinics today have X-ray imag-
ing equipment in the treatment room, applied for positioning the patient and
image guidance. This can either be a C-arm, which is a kV imaging system
for planar images, a cone beam CT for acquisition of 3D imaging or even a
full scale CT scanner on rails.
The X-ray CT is the working horse of medical imaging in cancer treatment
and proton CT is still at the prototype level. The need for accurate dose
predictions when applying protons is motivating the development of proton
CT based dose plans and the need for such a development increases further
with the rapid increase of the number of patients treated with protons. The
development of better treatment delivery techniques will also depend upon
an as correct as possible calculation of the proton range in a patient.
3.7 Pencil Beam Algorithms
A treatment plan will display the calculated dose distribution in the patient,
and will provide instructions for the dose delivery equipment. The input is
the patient geometry in terms of 3D CT information, and a radiation source
with a set of given parameters, such as energy, beam shape and dose rate [42].
47
Pencil beam algorithms are currently the standard dose calculation algo-
rithms for both scattered and scanned beam treatment. To calculate the
dose to a given volume the dose distribution of multiple pencil beams are
summed up. The calculated energy deposition is a function of radiological
depth, and the lateral energy diffusion kernel K. The radiological depth in
the patient accounts for the water-equivalent path length (WEPL) on the
trajectory toward the point in question. The kernels are generated by Monte
Carlo simulations or measurements, and they are radially symmetric for each
pencil beam. Pencil beam dose calculation algorithms are fast and generally
accurate, but have some shortcomings when introduced to inhomogeneities,
especially lateral inhomogeneities [42] [15].
The geometry input for a pencil beam algorithm is a CT voxel geometry,
and hence errors in the CT Hounsfield Unit value to proton stopping power
conversion will lead to errors in the pencil beam algorithm’s dose calculations.
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Chapter 4
The Monte Carlo Simulation
Method
An important goal of computer simulations within radiation therapy, is to
make sure that the patient receives the correct dose through a detailed calcu-
lation of the interaction processes that takes place in the volume or medium
under study. The Monte Carlo method is an accurate way of investigating
particle interactions in a medium, and it is considered to be the "gold stan-
dard" within computer simulations where the aim is mimicking the funda-
mental interaction processes in nature. Monte Carlo simulations are widely
used within radiation physics [15] [43].
Algorithms that are based on streams of random numbers are called Monte
Carlo algorithms. The mathematical foundation for the Monte Carlo method
is the Central Limit Theorem, which states that for a large number of inde-
pendent random variables, the mean will be normally distributed [15] [43].
Particle Tracking Particle transport is a typical physical process de-
scribed by cross sections, or interaction probabilities per unit length, and the
Monte Carlo method is applied when describing particle transport through
complex geometries. Each particle will have a pre-calculated probability for
the various processes that can occur, and their outcome. The uncertainty in
a Monte Carlo calculation depends on the number of histories, N. The error
will be proportional to 1/
√
N [15] [43].
The tracking geometry is a geometrical model with well-defined materials
that are characterized by their physical properties, such as elemental com-
position, electron density, mass density and mean excitation energy. This
model can portray any geometry the user wants to investigate, for example
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concrete shielding, beamlines or a patient anatomy. The results scored for
a simulation run can be parameters such as; dose, energy loss, fluence, etc,
this being determined by the user. The step size reflects the size of how far
the particle under study moves between each calculation of probabilities for
interactions in the defined geometry. The step size, chosen by the user, will
affect the outcome. The step size should be small, to ensure a good resolu-
tion. However, smaller step size increases the computation time and the user
should keep this in mind [15] [43].
Proton Physics
The accuracy of Monte Carlo simulations is obtained by the way the un-
derlying physics is implemented in the code. The Bethe-Bloch equation ad-
dressed in chapter 2 governs the energy loss for protons downwards to 2
MeV. Other relevant theories such as Moliere’s theory and Lewis’s theory
are implemented to ensure the scattering angle distribution and lateral dis-
placement [15]. When creating a geometry in a Monte Carlo simulation, the
elemental composition, the material density and the mean excitation energies
are implemented for that given material. The material properties are often
the latest recommended values given by ICRU (International Commission on
Radiation Units and Measurements).
Monte Carlo based treatment planning algorithms are currently emerging,
but are still too time consuming for daily clinical practice. However, as com-
puting power continuously increase, Monte Carlo planning can become avail-
able for clinical use within the near future. Scanned beam delivery is likely to
require a less complicated Monte Carlo model than scattered beam delivery
since the latter relies on many different components in the beam line.
4.1 Monte Carlo Codes
4.1.1 FLUKA
FLUKA, abbreviated from FLUktuierende KAskade, is a general purpose
tool for calculations of particle transport and interactions with matter. The
original application of FLUKA was accelerator shielding, but its application
now spans from investigating cosmic rays to radiation therapy. FLUKA can
simulate the interactions of about 60 different particles in a large energy
span. The FORTRAN language is used in the FLUKA Simulation tool [16].
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Capabilities and limitations
To provide accurate simulations, modern physics models are implemented
and the results checked against experimental data. Elements and composite
materials are implemented in the geometry, with the recommended material
properties from ICRU. The following list is a shortened excerpt from the
FLUKA manual [16], summarising the physics behind transport of charged
hadrons:
• Bethe-Bloch theory
• Mott correction to the Rutherford scattering cross section
• Optional delta-ray production and transport with account for spin ef-
fects and ionization fluctuations
• Shell and low-energy corrections derived from Ziegler
• Ionization potentials and density effect parameters according to Stern-
heimer, Berger and Seltzer
• Non-ionizing energy losses
• Displacements Per Atom (DPAs)
• Special transport algoritm, based on Molière’s theory of multiple Coulomb
scattering improved by Bethe
• Accurate treatment of boundaries and curved trajectories in magnetic
and electric fields
• Automatic control of the step
• Path length correction
• Spin-relativistic effects at the level of the second Born approximation
• Nuclear size effects (scattering suppression) on option
• Fano correction for heavy charged particle multiple scattering
• Single scattering: algorithm based on the Rutherford formula with
screening factor in the form used by Molière, integrated analytically
without any approximation. Nuclear form factors and spin-relativistic
corrections at the first or second Born approximation level accounted
for by a rejection technique
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• Correction for cross section variation with energy over the step
• Bremsstrahlung and electron pair production at high energy by heavy
charged particles, treated as a continuous energy loss and deposition
or as discrete processes depending on user choice
• Muon photonuclear interactions, with or without transport of the pro-
duced secondaries
FLUKA input
The user defined input to FLUKA is written in an ASCII standard input
file with the extension .inp. A typical FLUKA input file may contain the
following:
• Title and comments
• Description of the problem geometry
• Definition of the materials
• Material assignment
• Definition of the particle source
• Definition of requested detectors that the user wants to calculate varoius
physical quantities such as dose, fluence, etc.
• Definition of biasing schemes
• Definition of problem settings such as energy cut-offs, step size, etc.
• Initialisation of the random number sequence
• Starting signal and number of requested histories
The user can define the beam by choosing the particle, particle energy
or momentum, its starting position and direction directly in the input file.
For more complex beams such as a therapeutic beam of protons, a special
routine has to be written, compiled and linked to the input file.
52
Geometry
The user can define the geometry of the problem through assigning different
bodies and regions. A "body" can for example be a cylinder with a certain
position, length and radius, and a "region" is a zone with a material assigned
to it. The regions are defined by the bodies.
The geometry defined for the setup must be surrounded by a region of "black
hole". This is a fictitious material used to terminate particle trajectories.
4.1.2 Other Monte Carlo codes
Geant4
Geant4 (abbreviated from GEometry ANd Tracking) was designed in the
1990’s by an international collaboration of institutes, high energy physics
experiments and universities. The Geant4 Collaboration was established in
January 1999 in order to continue the development and improvement, and
to provide user support. Geant4 is based on object oriented programming in
C++, and is the successor of the GEANT series of software toolkits developed
by CERN [44].
MCNPX
MCNPX, abbreviated from Monte Carlo N-Particles eXtended, is written on
Fortran 90 and is developed by Los Alamos National Laboratory. It is mainly
used for simulation of nuclear processes [45].
VMCpro
VMCpro is a relatively new Monte Carlo tool, specifically developed to be
a fast Monte Carlo treatment planning system. It is developed in order to
simulate proton transport in human tissue [46].
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Chapter 5
Monte Carlo Simulations,
Methods and Results
The overall goal of this project has been an investigation of how a proton
beam interacts with matter and how an introduction of different materials in
the beam path will affect the key parameters relevant for a therapeutic proton
beam. The parameters most prominent from a particle therapy point of view
is; range, dose deposition and lateral spread. This chapter will describe the
simulations performed as well as their motivation and the results.
Tools The FLUKA Monte Carlo code (version 2011) and Varian Eclipse
Proton Planning have been used in this project. FLUKA was used in the two
first parts, the investigation of proton range and the creation of a spread-out
Bragg peak (section 5.1 and section 5.2), while both FLUKA and Eclipse
were used in the final part, creating and comparing simple treatment plans
(section 5.3). The program Gnuplot was used for plotting the data outcome.
FLUKA
As mentioned in chapter 4, FLUKA can simulate the interactions of about
60 different particles in a large span of energies.
All the geometry, the materials and the beam parameters are defined by
the user. The resulting energy deposition, dose and dose deposition, fluence
etc can be registered ("scored") for any region or plane defined by the user.
The parameters needed to perform the simulations are registered or linked
to the input card.
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Varian Eclipse Proton Planning
The Varian Eclipse Proton Planning is Varian’s treatment planning soft-
ware for proton therapy treatment planning. The proton dose calculation
algorithm supports both passive beam scattering and active beam scanning
technique. The software is configured to enable correspondence between the
treatment planning tool and a proton therapy machine. A proton beam de-
livery system has three main elements: the beam production area, the beam
transport line system and the clinical beam application area. Eclipse con-
tains no information about the beam production area or the beam line sys-
tem leading to the nozzle (beam application). The nozzle contains most of
the beam modifying elements used to manipulate the proton beam. The dose
reported to the user is calculated on a three-dimensional array of voxels on a
Cartesian grid. The calculation algorithm applied is the Proton Convolution
Superposition (PCS) version 11.0.30/31 [35].
5.1 Range - Effects of inhomogeneities
Simulation set-up In order to investigate the effect that inhomogeneities
have on the position of the Bragg peak, the FLUKA geometry editor, the
Geoviewer, was used to design a simple cubic phantom of homogeneous wa-
ter surrounded by air. Since the human body consists of approximately 60 %
water [47], a phantom made of water is an appropriate media to work with
in this context. The cube is 20× 20× 20 cm3. The simulations were typically
performed with 5 cycles, with 10 000 primary protons each, in a pencil beam
that was aimed in the positive z-direction with x = y = 0. A monoener-
getic proton pencil beam with a lateral Gaussian distribution spread, with
an FWHM value of 0.6 cm, was applied. The energies applied were 100 MeV
and 150 MeV. The FWHM value is an approximation to the conditions in a
real clinical beam [48]. The beam originates from z = −1 cm. When studying
the effect of inhomogeneities, a small volume of varying material was imple-
mented in the phantom geometry, positioned in the centre of the beam path,
located at 5 cm depth. The proton beam in a homogeneous water phantom
was used as a control set-up, the dose scoring from this reference phantom
is shown in figure 5.2. Figure 5.1 displays the phantom design in Geoviewer.
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(a) A 2D layout of the phantom set-up in the FLUKA Geoviewer
program.
(b) The water phantom in 3D view. Image from
the FLUKA Geoviewer program.
Figure 5.1: The 20 × 20 × 20 cm3 water phantom set up in FLUKA. At 5
cm depth there is a 1× 1× 1 cm3 cube of material that could be other than
water.
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(a) The dose deposition as a function of depth.
(b) The beam spot displayed as seen from the
beams’ eye-view.
Figure 5.2: FLUKA Monte Carlo simulation. A 2D display of the dose de-
position from a 150 MeV proton beam in water. Image a) shows the dose
distribution along the beam axis, with the distinct sharp dose deposition at
the end of the proton range, and with the beam broadening as a result of
scattering in the water. Image b) shows the dose deposition from the beam’s
point of view. A lateral spread of FWHM of 6 mm was applied for this
simulation.
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Bone
Human bone will vary in thickness and density depending on where in the
body the bone is located, on the age and gender of the patient and also the
on patient’s health.
In FLUKA there is a material database containing different compounds avail-
able for description of the geometry and materials in the variety of different
experiments that FLUKA is used for. There is a folder with biological com-
pounds such as blood, skin and bone. There are also descriptions of different
kinds of bone, with density ranging from 1.8 g/cm3 (cortical bone, ages 2-5
years) to 1.92 g/cm3 (cortical bone, adult). For this project the bone with
the density 1.85 g/cm3 was chosen as the standard. This bone density cor-
responds to a Hounsfield unit of +1450. Figure 5.3 shows the resulting dose
profile from a proton pencil beam when traversing into a water phantom with
a cube of bone positioned at 5 cm depth. As can be seen the Bragg peak is
shifted about 0.8 cm in the negative Z-direction compared to the Bragg peak
position for a similar proton beam in a homogeneous water phantom.
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(a) A 100 MeV proton beam
(b) A 150 MeV proton beam
Figure 5.3: FLUKA Monte Carlo simulation. Dose profile resulting from a
proton beam traversing a water phantom with a bone cube located at 5 cm
depth. Image a) result from a 100 MeV proton beam, image b) result from a
150 MeV proton beam
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Air
Examples of anatomic sites with a high concentration of air are the lungs, the
rectum and the intestines. The lungs are challenging to treat with radiation,
not only due to the big differences in density, but also due to the respiratory
movement. Head and neck cancers have been a treatment site that has been
considered appropriate to treat with particles, since there is little movement
of, in and around the target. The head and neck tumours can be relatively
deep-seated and will almost always be located adjacent to sensitive struc-
tures. In addition the head and neck can be positioned and fixated with high
precision and one can thus reduce the uncertainty due to patient movement.
However, there can be physiological changes that include anatomical varia-
tions that can alter the proton range. Examples of this are the nasal cavities.
These can be filled with fluid or they can be empty, in the latter case adding
an air cavity in the geometry. This cavity filling can change from day to day
or even during a day, causing an uncertainty in the water equivalent length
for the proton track leading towards the target volume.
The impact air will have on the proton range and behaviour was estimated
by using the phantom mentioned above, now with a cube of air located in
the beam path, at 5 cm depth. The resulting depth dose profile can be seen
in figure 5.4. As can be seen in the figure; the Bragg peak is shifted about
1.0 cm in the positive Z-direction compared to the situation for an otherwise
equal proton beam traversing a homogeneous water phantom.
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(a) A 100 MeV proton beam.
(b) A 150 MeV proton beam.
Figure 5.4: FLUKA Monte Carlo simulation. Dose profile resulting from a
proton beam traversing a water phantom with a cube of air located at 5 cm
depth. Image a) result from a 100 MeV proton beam, image b) result from a
150 MeV proton beam.
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Implants made of metal
Implants are commonly used to replace or support teeth, joints and bone
structures. The materials used varies with location and the functional cri-
teria for the implant. In radiation therapy, medical implants can introduce
complications. Since medical implants commonly consists of metal or metal
alloys, their densities can be 2-3 times higher than the density of bone, which
is otherwise the most dense material naturally occurring in the body. These
high density materials can cause artefacts in CT images, which in turn can
lead to errors in the dose calculations.
To investigate how the proton range is affected by implants, a cube of stain-
less steel (with density ρ = 8.0 g/cm3) and a cube of aluminium (with density
ρ = 2.7 g/cm3 was applied in the simulations. The resulting depth dose profile
can be seen in figure 5.5 and figure 5.6. The Bragg peak from the proton beam
traversing the steel cube is shifted about 4.5 cm in the negative Z-direction
and the Bragg peak from the proton beam traversing the aluminium cube
is shifted about 1.1 cm in the negative Z-direction, both positions are rela-
tive to the position of the Bragg peak from an otherwise equal proton beam
traversing a homogeneous water phantom.
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(a) A 100 MeV proton beam.
(b) A 150 MeV proton beam.
Figure 5.5: FLUKA Monte Carlo simulation. Dose profile resulting from a
proton beam traversing a water phantom with a stainless steel cube located
at 5 cm depth. Image a) result from a 100 MeV proton beam, image b) result
from a 150 MeV proton beam.
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(a) A 100 MeV proton beam.
(b) A 150 MeV proton beam.
Figure 5.6: FLUKA Monte Carlo simulation. Dose profile resulting from a
proton beam traversing a water phantom with an aluminium cube located at
5 cm depth. Image a) result from a 100 MeV proton beam, image b) result
from a 150 MeV proton beam.
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Summary of the Results
The range of the proton beam depends primarily on the density, atomic
number and mean ionization energy of the media traversed. The figures 5.3,
5.4, 5.5 and 5.6 show how the depth dose distribution of a proton pencil
beam is affected by a cube of the materials; bone, air, steel and aluminium
respectively, all in turn located at and from 5 cm water depth in the proton
beam path. In addition to a shift in the range, one can also notice a second
consequence of inserting a material in the water phantom. Due to scattering
in the phantom and the stochastic nature of the interaction mechanisms in
nature, some protons will pass by the cube and thus only interact in water.
This results in a small peak, located at the same depth as the Bragg peak
in the unperturbed homogeneous water phantom. This effect will be less
pronounced when the heterogeneity is broader or closer to the surface, since
a larger fraction of the scattered protons can not pass by the edges. The
proton fluence in 2D is shown in 5.7, here one can see that some protons pass
outside the bone volume. Table 5.1 summarizes the shift in the Bragg peak
position as a result of different material in the beam path.
Table 5.1: Range shift as a result of a 1 cm3 material cube in beam path.
Material Range shift compared to beam in a homogeneous water phantom.
Water 0 cm
Bone -0.8 cm
Air 1.0 cm
Aluminium -1.1 cm
Steel -4.5 cm
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Figure 5.7: FLUKA Monte Carlo simulation: The 2D proton fluence distri-
bution in units of protons pr cm2 pr primary particle. The phantom applied
in this simulation is a phantom with a cube of bone located at 5 cm depth
(marked as a small square in figure). Although most the protons traverse
through the cube, some have their path outside the bone volume, thus only
interacting with water.
Since various materials have different impact on the proton range, anatomic
sites with a heterogeneous structure need special care when considering pro-
ton therapy. In proton therapy clinics, the usual clinical routine when direct-
ing treatment fields towards the target volume in the dose planning stage
involves avoiding beam directions through heterogeneous media. Especially
sites with metal implants should be avoided, both due to the large impact
on proton range, but also in order to minimize imaging artefacts.
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5.2 Creation of Spread-out Bragg Peak
A tumour is extended in three dimensions and located at a certain depth in
the body. This means that the treatment unit should be able to deliver a
homogeneous dose to such a volume.
The Kleeman-Bragg rule gives us the relation between the energy (in MeV)
of the particle and the resulting range. For a proton beam traversing water,
the beam range (in cm) is given by equation 5.1 [49].
R = αEp0 (5.1)
Where α = 0.0022 and p0 = 1.77
In order to produce an SOBP one needs to add several beams of different
initial energy in a certain way. To obtain a flat dose plateau at a maximum
depth R0, with a width given by a fraction χ of the maximum depth, con-
sisting of n different energy intervals, the range of each contributing beam
(k = 1, 2, ...n) will be determined by equation 5.2.
rk =
[
1−
(
1− k
n
)
χ
]
R0 (5.2)
The corresponding energy of each beam is given by equation 5.3
ek =
(rk
α
) 1
p0 (5.3)
The shape of the SOBP depends on the weight of each beam. The distal
Bragg peak has the highest weight and the proximal Bragg peak has the
lowest weight. The weight wk of the beams is given in equation 5.4.
wk =

1− (1− 1
2n
)1− 1
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)]1− 1
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1
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)1− 1
p for k = n
(5.4)
The parameter p will vary slightly with energy, depth and the width of
the SOBP. A constant p-value of 1.77 will produce an SOBP, but the dose
plateau will be slightly tilted instead of flat, as noted by [49].
Using these equations one can create an SOBP. For this project the max-
imum depth of 15 cm for the dose plateau and an SOBP width of 5 cm was
chosen. This was performed by two different methods;
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• Modulation of the beam energy in a passive way by applying a range
modulator in the beam. This modulator was a ridge filter.
• Modulation of the beam energy in an active by altering the energy and
weight in the source.
5.2.1 Passive Modulation
When creating a therapeutic beam with passive modulation, the idea is to
apply material in the beamline, and let the beam interact with the material,
in order to produce a spread-out Bragg peak in the target volume. There
are numerous materials and designs to choose from, as mentioned in chapter
3. For this project an aluminium ridge filter was chosen. A ridge filter is a
static hardware component in the beamline and it is therefore less compli-
cated to simulate, than for instance a moving or rotating component. Still
the underlying principle is the same; the initially monoenergetic beam must
pass through the material in a way that makes the resulting dose deposition
shaped so that a spread-out Bragg peak is created. The position of the SOBP
can be adjusted by interchanging the range shifters in the beam line.
The ridge filter is composed of ridges with a curved triangular shape. Ac-
curate drawings of ridge filters in clinical use were not possible to retrieve
due to company non-disclosure policy. Hence, the dimensions of the ridge fil-
ter used in the simulations were designed based on the SOBP formula shown
above. In order to estimate how the thickness of aluminium affects the proton
range in water, simulations of a 150 MeV proton beam in water was carried
out while applying blocks of aluminium of varying thicknesses in front of the
water phantom. A linear relation between the aluminium thickness and the
resulting proton range in water was found and the resulting plot is shown in
figure 5.8.
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Figure 5.8: FLUKA Monte Carlo simulation. The resulting range in water
from a 150 MeV proton beam traversing a block of aluminium located in front
of the water phantom. The range in water depends linearly on the thickness
of the block. This relation was used to design the ridge filter.
Based on this thickness-range relation and the SOBP formula with depth,
modulation width and weighting factors, the ridge filter could be designed.
Again an energy modulation width of 5 cm was chosen, with 10 intervals.
Each ridge is 0.5 cm wide and about 2.7 cm deep, and consist of 20 "plates".
Each plate have a thickness that corresponds to the weight of that given beam
range, as can be seen in the figures 5.9 and 5.10. In table 5.2 the dimensions
for each step in the ridge is given.
Table 5.2: Alumium thickness and step width.
Aluminium height [cm] Step width [mm]
2.6 0.048
2.4 0.100
2.2 0.108
1.9 0.117
1.7 0.129
1.5 0.145
1.25 0.167
1.0 0.200
0.75 0.259
0.5 0.414
0.2 0.813
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(a) A 3D image of the ridge filter.
(b) A 3D close-up view of the ridge filter.
Figure 5.9: An aluminium ridge filter designed to create a spread-out Bragg
peak. The ridges has a step-like design, where the width of each step (in the
y-direction) corresponds the weight of the beam with energy determined by
the thickness (in the z-direction).
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Figure 5.10: A 2D image of the ridge filter.
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(a) The setup with 10 cm distance between the ridge filter
and water phantom.
(b) The setup with 2 m distance between the ridge filter
and water phantom.
Figure 5.11: Simulation geometry setup in FLUKA. The aluminium ridge
filter is positioned in front of the water phantom in order to create an SOBP
in the water phantom. In figure a) the distance between the ridge filter and
the water phantom is 10 cm, and in figure b) the distance is 2 m. The void
surrounding the setup is filled with air.
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Results
Dose Deposition When a ridge filter is used in a clinical beam, the pencil
beam originating from the particle accelerator will be scattered to create a
homogeneous proton field. In the simulations run in this project a proton
field with dimensions 5 × 5 cm2 was applied. The effect of distance in air
between the ridge filter and the phantom was investigated by positioning
the ridge filter 2 m away from the phantom, and 10 cm from the phantom
respectively, as illustrated in figure 5.11. The resulting SOBP is visualized
in figure 5.12. The dose profile shows a relatively flat dose plateau at the
desired depth (from 10 cm to 15 cm depth).
Figure 5.12: FLUKA Monte Carlo simulation. The SOBP as a result of a
monoenergetic proton field of 150 MeV traversing an aluminium ridge filter.
In particle therapy clinics, the ridge filter station where the required ridge
filter for each treatment situation will be inserted into the beamline is a
component of the beamline equipment and this station is usually located
around 2 meters from the patient. As can be observed in figure 5.13, the 2D
dose distribution is sharper and more confined when the ridge filter is located
close to the phantom. This is due to the scattering that the protons will
experience while traversing air. In clinics where this type of energy modulator
is used, the field is further adjusted to the target volume with collimators
and compensators, which in turn is located close to the patient.
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(a) The ridge filter located 2 m from the phantom.
(b) The ridge filter located 10 cm from the phantom.
Figure 5.13: FLUKA Monte Carlo simulation. The 2D dose distribution in a
water phantom, resulting from a 5× 5 cm2 150 MeV proton beam traversing
an aluminium ridge filter located a) 2 meters from the phantom, and b) 10
cm from the phantom.
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Neutron Production In addition to the investigation of dose distribu-
tion, the issue of radiation induced secondary particles is inherent in particle
therapy. When beam losses occur, secondary radiation will be produced. By
scoring the neutron fluence in the whole system, one can see that beamline
components can induce neutron dose that is difficult to completely avoid. To
reduce unwanted dose from radiation induced neutrons, the energy modula-
tor should be positioned at some distance from the patient. If the ridge filter
were located closer to the patient, neutron contamination from the ridge filter
would be more pronounced. In figure 5.14 the neutron fluence for the whole
geometry system, ie the ridge filter, the water phantom and the surrounding
air, is visualized. This production of neutrons would come in addition to the
neutron contamination from the collimator systems that is needed to tailor
the field in order to limit the dose to the target volume. In order to thor-
oughly quantify the production of neutrons in all steps leading towards the
patient, and its resulting additional dose to the patient, one needs a detailed
model of a clinical beamline and gantry. This is beyond the scope of this
master thesis project.
Figure 5.14: FLUKA Monte Carlo simulation. The neutron fluence is shown
in color wash for the whole geometry system, with the ridge filter located 2
meters away from the phantom.
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5.2.2 Active Modulation
In order to create an SOBP via active modulation, the energy distribution
and beam position needed to be modulated by editing the source.f user
routine in FLUKA. The source.f file must be written in FORTRAN code,
compiled and linked to the input file for the simulation.
The SOBP formulas 5.2, 5.3 and 5.4 shown above were used to generate
a list of energies and corresponding weights, reflecting the probabilities for
each proton to be assigned that given energy. A do-loop sampled the ener-
gies and cumulative weights from the list and assigned it to the particles
generated. Details from the script can be found in Appendix B. In table 5.2
the energies and weights needed in order to create an SOBP with maximum
depth R0 = 15 cm, modulation width 5 cm and 10 energy intervals are listed.
For these parameters, a p-value of 1.6 was chosen as it gave a resulting SOBP
with a flat dose plateau at the desired depth. Table 5.3 summarizes 10 en-
ergy intervals, ie 11 beam energies and corresponding weights, which could
be applied in order to create an SOBP with maximum depth 15 cm and a
modulation width of 5 cm.
Table 5.3: Beam energies and weights calculated to create a spread-out Bragg
peak with maximum depth of 15 cm, modulation width of 5 cm and 10 energy
intervals.
Range in water [cm] Energy [MeV] Weight
10.0 116.5 0.01905
10.5 119.8 0.04007
11.0 123.0 0.04314
11.5 126.1 0.04691
12.0 129.2 0.05167
12.5 132.2 0.05793
13.0 135.1 0.06667
13.5 138.1 0.07996
14.0 140.9 0.10366
14.5 143.7 0.16577
15.0 146.5 0.32517
In order to obtain a smooth curve for the dose plateau covering the target
volume, the SOBP was split into 51 energies with equally spaced energy
intervals. The energies and weights were calculated and implemented in the
source.f user routine. The energies were listed as DATA ENEDGE in units of GeV
and the weighting factors were added to a cumulative spectrum listed in DATA
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CUMPR. The full input card and source.f script are shown in appendix B.
The simulations were run in 5 cycles each with 500 000 primaries in order
to obtain good statistics and a smooth dose distribution. The simulation ran
for about 1-2 hours.
Results
For the active modulation, a system resembling a spot scanning system was
developed. The result is displayed in figure 5.15.
Figure 5.15: FLUKA Monte Carlo simulation. The SOBP produced with
active modulation of the beam in FLUKA. The resulting beam is composed
of 50 energy intervals, ie 51 equally spaced beam energies ranging from 116
MeV to 146 MeV.
The weighting scheme is generated with formula 5.4, referred to above.
To find the optimal weighting of the energies to obtain the desired SOBP,
the p-value needs to be adjusted. The p-value can vary for different depths
and energies. For the depth chosen for this project (5 cm SOBP covering
the depth from 10 cm to 15 cm), the p-value 1.6 proved to be an adequate
choice. Figure 5.16 shows the resulting SOBP when using the three different
p-values (1.3, 1.6, and 1.9). The dose plateau is tilted in one direction or the
other if a suitable p-value is not applied.
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Figure 5.16: FLUKA Monte Carlo simulation. The SOBP plotted with three
different weighting schemes. The beam energies are identical, but the p-value
from the weighting formula 5.4 is different in the three cases with the p-values;
1.3, 1.6 and 1.9.
When the beam in not slowed down with material in the beam line, as
is the case with passive modulation, the resolution of the treatment avoids
to be degraded during energy modulation. In this context, the resolution of
the treatment refers to in which degree the dose deposition is confined to
the target volume, regardless of the shape and position of the target volume.
Because the beam will be scattered both in the modulators and in the air in
front of the patient, passive modulation will lead to a less precisely confined
treatment beam than what is achievable with active modulation. With active
modulation there will still be some scattering of the beam, but the newest
gantries in proton clinics today, such as the Gantry 2 at PSI in Villigen,
Switzerland, will enable the distance in air to be as short as possible [48].
This is obtained by a mechanism that allows an adjustment of the treatment
snout position relative to the patient surface during treatment. The scattering
of the beam inside the patient will still determine the lowest limit for the
treatment resolution.
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Figure 5.17: FLUKA Monte Carlo simulation. SOBP of modulation width 5
cm. Passive modulation and active modulation.
Figure 5.17 displays the SOBP produced both with passive (solid line)
and with active modulation (dashed line). The distal dose falloff is steepest
when applying active modulation. However it is important to note that there
are ways of making the passive modulation more well defined than it was done
in this work. By using other types of materials in the modulator, for instance
PMMA, and in addition applying collimation systems in the beamline, one
can obtain a sharper dose deposition than the one presented in figure 5.17.
To simulate this would require detailed descriptions and technical drawings
of a real clinical beamline, and this is beyond the scope of this master thesis
project.
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5.3 Homogeneous Dose to an Extended Volume
In the final simulations made in this project, the knowledge obtained in
the work presented in the previous sections was applied in order to create
treatment plans in FLUKA, and to compare these with the output from
equivalent treatment plans created in Eclipse.
5.3.1 Phantoms
A few basic phantoms were designed. The basic geometry was, as in the
previous sections, a water cube with dimensions 20×20×20 cm3. The volume
to be treated is a 5× 5× 5 cm3 cube located at 10 cm depth with the central
beam axis in its center.
• The first case is the homogeneous water phantom as described above.
This is the simplest case to simulate, and one should expect the output
from FLUKA and Eclipse to be almost identical.
• In order to see how the therapeutic beam is affected by different mate-
rials, a volume of bone, air or aluminium was added to the phantom.
The volume was 1 cm thick (in z-direction), and with an area of 5× 5
cm2, located in the middle of the central beam axis to symmetrically
cover the entrance of the treatment volume. In order to reach the target
volume, the energy assigned to the proton beam should be adjusted ac-
cording to the water equivalent depth in the phantom. The results from
the previous sections were used to make these adjustments in FLUKA.
The phantom design is shown in figure 5.18.
• The final phantom case is an asymmetrical set-up where the material
volume from the previous case has been split in half, and thus only one
half of the beam particles had the material in its forward path. Since
a material other than water is blocking half the entrance to the target
volume, the algorithm is modified to assign one set of energies to half
the field, and a different set of energies to the other half of the field.
5.3.2 Simulation Set-up in Eclipse
In treatment planning software such as Eclipse, the input is the file con-
taining the patient geometry, and the source and beamline properties and
constraints. In this project treatment plans were generated using the multi-
field uniform dose scanning technique, with one field direction. The treatment
volume was defined as a Planning Target Volume (PTV), a 5 × 5 × 5 cm3
81
water cube located at 10 cm depth. For all the treatment plans, the lateral
margins were set to 0.5 cm and the distal and proximal margins were set to 0
cm. As is common in all treatment planning systems, the target volume and
the geometry (organ definition and delineation) is the input initially given
by the user. The beam energy and the fluence weighting is calculated by the
algorithm in order to meet the criteria set by the user. The user can make
changes to the fluence weighting scheme after evaluating the initial dose dis-
tribution proposed by the algorithm.
In the clinical routine the goal is to create treatment plans with an accept-
able dose coverage of the target volume, and at the same time keep the dose
to the surrounding organs on an as low as possible level and according to
the latest recommendations. A typical measure for the homogeneity of the
dose in the target volume is the maximum and minimum dose in the target,
and the fraction of the target that receives 100% dose. A "good" coverage
can for instance be when the dose in target (PTV) lies between 95% and
105% of the prescribed dose. One should note that the purpose of this work
is not to make clinically optimized treatment plans, but to investigate how
the treatment planning system calculate the dose when introduced to various
materials blocking the treatment volume (PTV). In table 5.4 the parameters
modulation width, minimum energy and maximum energy from the Eclipse
set-up is presented. Note that the target volume, a cube of 5 × 5 × 5 cm3
located at and from 10 cm depth, is the same for all the treatment plans.
After defining the target volume and setting the margins as mentioned above,
the dose was calculated.
Table 5.4: Eclipse values
Fhantom SOBP width Minimum energy Maximum energy
Homogeneous water phantom 5.09 cm 116.3 MeV 146.7 MeV
Bone volume, symmetric case 5.83 cm 120.2 MeV 151.7 MeV
Air volume, symmetric case 6.04 cm 113.2 MeV 143.8 MeV
Aluminium volume, symmetric case 6.51 cm 127.0 MeV 155.5 MeV
Bone volume, asymmetric case 5.77 cm 119.9 MeV 151.4 MeV
Air volume, asymmetric case 6.55 cm 109.6 MeV 147.2 MeV
Aluminium volume, asymmetric case 6.62 cm 120.3 MeV 156.3 MeV
5.3.3 Simulation Set-up in FLUKA
In order to create the treatment plans in FLUKA, the SOBP energy distribu-
tion had to be implemented in the source.f user routine. In addition, several
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beam adjustments were done in order to make the FLUKA beam resemble an
as realistic treatment beam as the beam modelled in Eclipse. This includes
a Gaussian spread in both lateral position and in energy, which will add
a certain spread or "blurriness" the dose deposition. Table 5.5 summarizes
the modulation width, minimum energy and maximum energy applied in the
treatment plans created in FLUKA.
Table 5.5: FLUKA values
Fhantom SOBP width Minimum energy Maximum energy
Homogeneous water phantom 5.0 cm 116.2 MeV 146.5 MeV
Bone volume, symmetric case 5.0 cm 121.4 MeV 150.9 MeV
Air volume, symmetric case 5.0 cm 109.5 MeV 140.9 MeV
Aluminium volume, symmetric case 5.0 cm 122.7 MeV 152.0 MeV
Bone volume, asymmetric case 5.0 cm 116.2 MeV 150.9 MeV
Air volume, asymmetric case 5.0 cm 109.6 MeV 146.5 MeV
Aluminium volume, asymmetric case 5.0 cm 116.2 MeV 152.0 MeV
In the source.f user routine the spread in energy and lateral position is
given with the Gaussian distributed parameters RGAUSS, RGAUS1, RGAUS2.
The first gives a spread of energy with σ = 0.008, and RGAUS1 and RGAUS2
gives a lateral Gaussian distribution with σ = 0.37 cm.
* Kinetic energy of the particle (GeV)
CALL FLNRRN(RGAUSS)
TKEFLK (NPFLKA) = ENERGY*(1+0.008D0*RGAUSS)
* Particle coordinates
* To get a lateral dose profile with a gaussian blurryness at the edges
CALL FLNRR2(RGAUS1, RGAUS2)
XFLK (NPFLKA) = (-2.7 + 0.37D0*RGAUS1)+ FLRNDM(DUMMY)*5.4
YFLK (NPFLKA) = (-2.7 + 0.37D0*RGAUS2)+ FLRNDM(DUMMY)*5.4
ZFLK (NPFLKA) = -1.0
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(a) The FLUKA phantom geometry.
(b) The Eclipse phantom geometry.
Figure 5.18: Phantom design, the symmetric case. The volume of different
materials is located at 5 cm depth. In image a) the FLUKA geometry is
illustrated while in image b) the Eclipse geometry is illustrated. The phan-
toms were designed independently in both systems, but the dimensions and
densities are similar in both systems.
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5.3.4 Results
The following sections will focus on the results from the final part of the
project; creating and comparing treatment plans with the Eclipse Proton
Planning software and with the FLUKA Monte Carlo code. The properties
displayed and compared are the dose profile in depth (longitudinal), and the
dose profile in the lateral direction. In addition the 2D dose deposition in
color wash will display and give an impression about how the two meth-
ods handle the various materials and material positions implemented to the
phantoms.
One discrepancy between the FLUKA and Eclipse dose profiles that was
present in all the treatment plans was the calculated entrance dose. As can
be observed in the figures 5.19 through 5.36, the calculated entrance dose is
generally slightly higher for the Eclipse calculation than for the FLUKA cal-
culation, especially for the first 2-3 cm. The gap decreases towards the SOBP.
This discrepancy was not further investigated, due to time constraints.
The following section will summarize the result from each phantom case.
Symmetric Phantoms
The figures 5.19 to 5.30 illustrate the resulting dose profiles for the phantoms
with a symmetric geometry.
Homogeneous water phantom: The figures 5.19 and 5.20 display the dose
deposition in the homogeneous water phantom in FLUKA and in Eclipse. As
expected, the dose deposition for this phantom set-up is almost identical for
the two systems. The SOBP calculated in Eclipse is slightly wider than the
SOBP in FLUKA. This is due to how the SOBP has been determined for the
two systems. In Eclipse the width is determined by the PTV defined as the
target volume. The PTV is 5 cm in width, and Eclipse calculates the energies
and weighting needed in order to provide an as good as possible coverage of
the target volume. Despite setting the distal and proximal margins to zero,
the calculation algorithm still adds the required spots in order to ensure that
the PTV is covered in full depth. In FLUKA the energies are calculated from
the formulas 5.2, 5.3 and 5.4, not taking into account the clinical purpose
of the PTV. In figure 5.21, the energies in the FLUKA dose plan has been
adjusted in order to fit the Eclipse dose profile. The result is two dose profiles
that are almost identical.
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(a) Longitudinal (depth) dose profile from FLUKA and Eclipse.
(b) Lateral dose profile from FLUKA and Eclipse.
Figure 5.19: FLUKA Monte Carlo simulation and Eclipse dose calculation.
Results from dose prescription and calculation in a homogeneous water phan-
tom. The target volume is located at 10 cm depth. In a) the longitudinal
(depth) dose profile is shown and in b) the lateral dose profile is shown.
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(a) The 2D dose distribution in FLUKA.
(b) The 2D dose distribution in Eclipse.
Figure 5.20: FLUKA Monte Carlo simulation and Eclipse dose calculation.
The 2D dose distribution in the phantom, a) in FLUKA and b) in Eclipse.
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Figure 5.21: FLUKA Monte Carlo simulation and Eclipse dose calculation.
Longitudinal dose profiles compared for FLUKA and Eclipse. In this sim-
ulation the energies and SOBP width from Eclipse are implemented into
the FLUKA source routine, resulting in a dose profile almost identical. The
energy distribution ranges from 115.5 MeV to 147.1 MeV.
Symmetric water phantom with bone volume: The figures 5.22 and
5.23 display the dose deposition in the water phantom with a bone volume
located at 5 cm depth. The SOBP dose deposition are in good agreement for
the two systems, however as with the previous case, Eclipse adds some extra
SOBP width. Again a second FLUKA simulation was carried out, mimicking
the energies and SOBP width obtained from Eclipse. The resulting dose
profile is plotted in figure 5.24. The most striking feature, is the difference
between the two calculations appearing at the depth of the bone volume.
The FLUKA dose curve experience a discrepancy at the location of the bone,
both with respect to dose level, which decrease about 5 % in the bone, and
to the slope of the dose curve. On the other hand, the Eclipse dose curve
only displays an increased slope at the same point. The reason for this is
the different approach to interpretation of the geometry in the two systems.
The Eclipse geometry has the Hounsfield Unit with a corresponding proton
stopping power for the bone volume to calculate from, while FLUKA has the
full elemental composition and the physical properties of the bone volume
available. This difference in dose calculation will be further addressed in
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section 5.3.5.
(a) Longitudinal (depth) dose profile.
(b) Lateral dose profile.
Figure 5.22: FLUKA Monte Carlo simulation and Eclipse dose calculation.
Dose profiles in the water phantom with a volume of bone located at 5 cm
depth. a) Longitudinal (depth) dose profile and b) lateral dose profile.
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(a) The 2D dose distribution in FLUKA.
(b) The 2D dose distribution in Eclipse.
Figure 5.23: FLUKA Monte Carlo simulation and Eclipse dose calculation.
The 2D dose distribution in the phantom with a volume of bone located at
5 cm depth, a) in FLUKA and b) in Eclipse.
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Figure 5.24: FLUKA Monte Carlo simulation and Eclipse dose calculation.
Longitudinal dose profiles compared for FLUKA and Eclipse in the water
phantom with a volume of bone located at 5 cm depth. In this simulation
the energies and SOBP width from Eclipse are implemented into the FLUKA
source routine, resulting in an almost identical SOBP. The energy distribu-
tion ranges from 117.5 MeV to 152.0 MeV.
Symmetric water phantom with a volume of air: The figures 5.25
and 5.26 display the dose deposition in the water phantom with a volume of
air located at 5 cm depth. For this case Eclipse adds an additional 1.0 cm to
the SOBP, which is visible in the distal part of the target. In figure 5.27, the
energies and SOBP width from Eclipse is implemented in the FLUKA source
code, leading to a good agreement between FLUKA and Eclipse concerning
the proximal and distal edge of the SOBP. As in the previous case, the
FLUKA dose curve experience a discrepancy at the location of the air volume.
The slope decreases to almost zero, and the dose level drops about 15 % in
the air volume. At the same time the Eclipse dose curve experience the same
decrease in slope, but not the change in dose level. This phenomena are
further addressed in section 5.3.5.
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(a) Longitudinal (depth) dose profile.
(b) Lateral dose profile.
Figure 5.25: FLUKA Monte Carlo simulation and Eclipse dose calculation.
Dose profiles in the water phantom with a volume of air located at 5 cm depth.
Image a) shows the longitudinal (depth) dose profile and b) the lateral dose
profile.
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(a) The 2D dose distribution in FLUKA.
(b) The 2D dose distribution in Eclipse.
Figure 5.26: FLUKA Monte Carlo simulation and Eclipse dose calculation.
The 2D dose distribution in the phantom with a volume of air located at 5
cm depth, a) in FLUKA and b) in Eclipse.
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Figure 5.27: FLUKA Monte Carlo simulation and Eclipse dose calculation.
Longitudinal dose profile compared for FLUKA and Eclipse in water phantom
with a volume of air located at 5 cm depth. In this simulation the energies and
SOBP width from Eclipse are implemented into the FLUKA source routine,
resulting in an almost identical SOBP. The energy distribution ranges from
110.1 MeV to 144.3 MeV.
Symmetric water phantom with aluminium volume: The figures
5.28 and 5.29 display the dose deposition in the water phantom with an
aluminium volume located at 5 cm depth. Eclipse adds an additional 0.5
cm to the SOBP, which is apparent in the distal part of the SOBP. Figure
5.30 shows the longitudinal dose profiles as the input energies in FLUKA is
adjusted to match the Eclipse energy distribution. The FLUKA dose curve
displays a large deviation at the position of the aluminium, causing a decrease
in dose level of about 17 %. And as with the previous cases, the only impact
on the Eclipse dose curve is the increase of the slope of the dose curve.
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(a) Longitudinal (depth) dose profile.
(b) Lateral dose profile.
Figure 5.28: FLUKA Monte Carlo simulation and Eclipse dose calculation.
Dose profiles in the water phantom with a volume of aluminium located at
5 cm depth. Image a) shows the longitudinal (depth) dose profile and b) the
lateral dose profile.
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(a) The 2D dose distribution in FLUKA.
(b) The 2D dose distribution in Eclipse.
Figure 5.29: FLUKA Monte Carlo simulation and Eclipse dose calculation.
The 2D dose distribution in the phantom with a volume of aluminium located
at 5 cm depth, a) in FLUKA and b) in Eclipse.
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Figure 5.30: FLUKA Monte Carlo simulation and Eclipse dose calculation.
Longitudinal dose profiles compared for FLUKA and Eclipse in the water
phantom with a volume of aluminium located at 5 cm depth. In this simu-
lation the energies and SOBP width from Eclipse are implemented into the
FLUKA source routine, resulting in an almost identical SOBP. The energy
distribution ranges from 122.6 MeV to 154.6 MeV.
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Asymmetric Phantoms
Figures 5.31 through 5.36 illustrate the resulting dose profiles in the phan-
toms with an asymmetric geometry. An asymmetric phantom design will
illustrate how the dose deposition will be affected as the beam must pass an
interface with a high density gradient, orthogonal to the beam direction.
In addition to the discrepancy between FLUKA and Eclipse concerning the
dose calculations at the position of the inhomogeneity, there is a difference
in how the two models generate the beam distribution assigned to cover the
target volume with homogeneous dose. In FLUKA the method used to create
this distribution of proton energies were the approach where one half of the
phantom (y=[-10:0]) was treated like a homogeneous water phantom, while
the other half of the phantom (y=[0:10]) was treated like the phantom with a
material volume inserted into the beam path, as described above. Eclipse has
a different approach. As can be observed in the 2D dose distribution, the dose
distribution in the whole system seems altered by the block of material other
than water covering half the entrance area for the beam path leading towards
the target volume. The lateral field in Eclipse is generally broader and more
asymmetric than in FLUKA, despite the target volume, the 5 × 5 × 5 cm3
cube located at 10 cm depth, is constant for all the treatment plans. The
details in the calculation algorithm is not available for the Eclipse user, and
the algorithm can not be edited by the user. However, Eclipse is a tool cre-
ated for clinical use and when faced with heterogeneous geometry and sharp
density edges the calculation algorithm invokes additional beam spots in or-
der to cover the target volume with dose. In all the simulations there is a
slight discrepancy in the position of the SOBP concerning the proximal and
the distal edge between FLUKA and Eclipse. As in the case with the sym-
metrical phantoms presented in the previous section, the energies calculated
to produce the SOBP are not identical for the two systems. This discrepancy
was addressed in the previous section and will not be elaborated in this sec-
tion. The characteristics considered regarding the SOBP in this section are
the shape of the SOBP and the slope and sharpness of the distal dose falloff.
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Asymmetric water phantom with bone volume: Figures 5.31 and
5.32 display the longitudinal, lateral and 2D dose distribution calculated with
FLUKA and Eclipse. The SOBP dose plateau from both programs follow the
same shape, this is the case also for the shape of the distal falloff. The lateral
dose profile differs by 1.0 cm at the side with the bone volume. Like in the
previous examples, the FLUKA and Eclipse algorithms approach the dose
calculation differently. The FLUKA routine distributes the dose without any
clinical considerations towards the volume. Being a system developed for
clinical use, Eclipse adds beam spot to the lateral edges in order to fully
cover the target volume, hence a broader lateral distribution will appear.
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(a) Longitudinal (depth) dose profile.
(b) Lateral dose profile.
Figure 5.31: FLUKA Monte Carlo simulation and Eclipse dose calculation.
Dose profiles in the water phantom with a volume of bone located at 5 cm
depth, thus blocking half the target volume as seen in the beam’s eye view.
The figure displays a) the longitudinal (depth) dose profile and b) the lateral
dose profile, averaged at the centre of the PTV (at 12.5 cm depth).
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(a) The 2D dose distribution in FLUKA.
(b) The 2D dose distribution in Eclipse.
Figure 5.32: FLUKA Monte Carlo simulation and Eclipse dose calculation.
The 2D dose distribution in a water phantom with a volume of bone located
at 5 cm depth, thus blocking half the target volume as seen in the beam’s
eye view. The figure displays the 2D dose distribution a) in FLUKA and b)
in Eclipse.
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Asymmetric water phantom with air volume: Figures 5.33 and 5.34
display the longitudinal, lateral and 2D dose distribution calculated with
FLUKA and Eclipse. Air can be challenging for dose planning of a proton
beam. A beam will deposit very little energy in air, but beam scattering
and the corresponding beam divergence can be significant for a proton beam
traversing through air. The SOBP from FLUKA and Eclipse are consistent
when compared to each other and the distal dose falloff has the same shape,
due to the air disturbance the distal edge is less sharp than the distal shape
calculated for a homogeneous water phantom. As with the calculations for
homogeneous phantoms, Eclipse adds some width to the SOBP. From the
2D dose distribution one can see that the Eclipse dose distribution in the
homogeneous part of the phantom is altered by the volume of air located on
the other side. A similar dose disturbance can not be seen in the FLUKA
calculated dose deposition. As previously mentioned, the FLUKA beam al-
gorithm treats the homogeneous side like a homogeneous geometry, and the
inhomogeneous side like an inhomogeneous geometry, ie the beam assigned
to cover the target at one lateral edge is not influenced by the geometry at
the other lateral edge, 5 cm away.
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(a) Longitudinal (depth) dose profile.
(b) Lateral dose profile.
Figure 5.33: FLUKA Monte Carlo simulation and Eclipse dose calculation.
Dose profiles in the water phantom with a volume of air located at 5 cm
depth, thus blocking half the target volume as seen in beam’s eye view. The
figure displays a) the longitudinal (depth) dose profile and b) the lateral dose
profile.
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(a) The 2D dose distribution in FLUKA.
(b) The 2D dose distribution in Eclipse.
Figure 5.34: FLUKA Monte Carlo simulation and Eclipse dose calculation.
2D dose distribution in the phantom with a volume of air located at 5 cm
depth, thus blocking half the target volume as seen in the beam’s eye view.
The figure displays the dose distribution a) in FLUKA and b) in Eclipse.
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Asymmetric water phantom with an aluminium volume: Figures
5.35 and 5.36 display the longitudinal, lateral and 2D dose distribution cal-
culated with FLUKA and Eclipse. The dose profiles from the asymmetric
phantom with aluminium covering half the treatment field, is consistent in
FLUKA and Eclipse, both regarding SOBP, lateral dose profile and 2D dose
distribution. Some discrepancy between the two methods is visible in the
SOBP. However this is due to where the dose profile is plotted in the geome-
try. For all the treatment plans, the center of the treatment volume has been
the standard position for the average dose output. The inconsistency can be
caused by the deviation between the Eclipse versus FLUKA geometry design.
When creating volumes in FLUKA, the exact coordinates are assigned by the
user. The exact coordinates are not available as input numbers when creating
volumes in Eclipse due to the limited resolution of the geometry. This can
lead to a slight variation in the eclipse geometry compared to FLUKA, in
the order of 1-2 mm.
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(a) The longitudinal (depth) dose profile.
(b) Lateral dose profile.
Figure 5.35: FLUKA Monte Carlo simulation and Eclipse dose calculation.
Dose profiles in the water phantom with a volume of aluminium located at
5 cm depth, thus blocking half the target volume as seen in the beam’s eye
view. The figure displays a) the longitudinal (depth) dose profile and b) the
lateral dose profile.
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(a) The 2D dose distribution in FLUKA.
(b) The 2D dose distribution in Eclipse.
Figure 5.36: FLUKA Monte Carlo simulation and Eclipse dose calculation.
2D dose distribution in the phantom with a volume of aluminium located
at 5 cm depth, thus blocking half the target volume as seen in the beam’s
eye view. The figure displays the dose distribution a) in FLUKA and b) in
Eclipse.
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5.3.5 Calculated Dose and Energy Loss
The Bethe Bloch equation is expressing energy loss by charged particles as
they traverse matter. The parameters specific for the absorbing material tra-
versed are density ρ in units of [ g
cm3
], the ratio of atomic number and atomic
weight Z
A
, and finally the mean ionization energy I in units of [eV ].
Table 5.6: Mean ionization energy for various materials [6]
Material I [eV ]
Graphite 78
Mg 156
Cu 322
Al 166
Fe 286
Au 790
Pb 823
Si 173
NaI 452
N2 82
O2 95
H2O 75
lucite 74
Air 85.7
BGO 534
Plastic scint. 64.7
From the simulations performed in FLUKA one can see a discontinuity
in the depth dose curve at the point where the material volume is located. In
the Eclipse calculations these discontinuities are not present. This is partly
due to the information available in a microscopic Monte Carlo simulation tool
as FLUKA as opposed to Eclipse, which applies simplifications that does not
provide or apply the same amount of information into the algorithm.
In FLUKA, the geometry input is of a different kind than the geometry
input in Eclipse. When the phantoms were designed in FLUKA, the mate-
rials in the geometry have been assigned with elemental composition and
tabulated material properties. As a result of this, FLUKA has the informa-
tion required to solve the Bethe-Bloch equation throughout the geometry.
On the other hand, Eclipse has a more limited set of parameters available,
and more approximations are applied in order to calculate the dose based on
the geometry input. In the clinical routine, a set of slice-by-slice CT scans of
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the patient is imported into the treatment planning software, in this instance
Eclipse. The proton stopping power is estimated based on these CT numbers,
using the stoichiometric method addressed in section 3.5.1. When designing
a phantom in Eclipse, the user can create different shapes and assign vari-
ous materials into the geometry. However, the user assigns only a HU to the
material in a phantom geometry, and Eclipse calculates the physical density
of the material based on the HU value the user has provided. Two materials
with the same physical density but with different elemental composition and
mean ionization energy will by this method be treated as identical materials
in a phantom created in Eclipse. The algorithm models only water, ie there
are no other materials in an Eclipse geometry than water, only the physical
density can vary. The CT based HU value is interpreted into stopping power,
hence the "water" is scaled by altering the density. The other main parame-
ters affecting energy deposition, for instance the mean ionization energy, will
be universally the same for the whole Eclipse geometry [50]. This means that
when adding for instance a structure of aluminium into the phantom, one
can only apply a Hounsfield number which Eclipse in turn interprets to a
physical density. Aluminium has the physical density ρ = 2.7 g/cm3, which
would give a HU value of around +2800. For Eclipse a structure of aluminium
will appear to be a volume of very dense water, still with a mean ionization
energy of 75 eV [35], as opposed to 166 eV which is the mean ionization en-
ergy of aluminium.
To investigate this "water density scaling method" simulations were run in
FLUKA with materials of constant density, but with different elemental com-
positions. In figure 5.37 one can see the resulting depth dose curve of a 150
MeV proton beam hitting a target consisting of; bone, beryllium and epoxy
respectively. In the material database in FLUKA these materials are listed
with the same physical density, ρ = 1.85 g/cm3. The material database even
contains bone with equal density, but with different mean ionization energy.
The result when scoring the dose from a 150 MeV proton beam can be seen in
figure 5.38. To investigate how this effect can alter the position of an SOBP,
a bone volume of 4 cm was positioned in a water phantom geometry, from 3
cm to 7 cm depth. The result from a simulation on this set-up can be seen
in figure 5.39. As can be seen in this figure, the distal falloff is pushed about
2-3 mm deeper, ie about 2 % of the total range, for the bone with the highest
mean ionization energy (106.4 eV) compared to the bone with an ionization
energy of 91.9 eV. These variations in mean ionization energy will not be
possible to identify in a CT image, thus an Eclipse dose calculation based on
this CT geometry would give two identical curves.
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Figure 5.37: FLUKA Monte Carlo simulation. Depth dose profile from a 150
MeV proton beam in 3 different materials; bone, beryllium and epoxy. These
materials all have the same density.
Figure 5.38: FLUKA Monte Carlo simulation. Depth dose profile from a 150
MeV proton beam in 2 different types of bone. The densities for these two
types of bone are the same (1.85 g/cm3), but the elemental composition and
mean ionization energy are different. The solid line shows the dose in bone
with a mean ionization energy of 106.4 eV, while the dashed line shows the
dose in bone with a mean ionization energy of 91.9 eV.
110
Figure 5.39: FLUKA Monte Carlo simulation. The SOBP with the same
energy spectrum and weight distribution impinging on a water phantom with
a 4 cm thick volume of bone located at 3 cm depth. As in the previous figure,
the density of the bone is similar in both cases, however the mean ionization
energy is different.
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Chapter 6
Conclusion and outlook
The overall purpose of this project has been to simulate a therapeutic pro-
ton beam using the FLUKA Monte Carlo code, and to create proton therapy
plans with a clinically optimized proton therapy dose planning software, in
order to illustrate the difference in calculated dose using Monte Carlo sim-
ulation compared to a commercial treatment planning system, the Varian
Eclipse proton planning software.
A spread-out Bragg peak was created with the use of both passive and active
energy modulation, based on the formula presented by [49]. In the passive
case, an aluminium ridge filter was designed with thickness and widths cal-
culated to produce an SOBP from a 150 MeV proton field. The ridge filter
was modelled based on acquired information regarding the stopping power
of aluminium and the weighting formula 5.4 required to create an SOBP.
The resulting SOBP produced with the ridge filter shows a satisfactory dose
profile for this purpose, a confined dose plateau at the desired depth. The
scattering of the beam in the ridge filter, and in the air between the filter
and the phantom, makes the distal falloff less steep than when no material
is present in the beam.
A sharper SOBP was obtained with the use of active energy modulation.
Based on the SOBP formulas by [49], a user subroutine was written and
linked to the FLUKA input card. The resulting SOBP displayed a flat dose
plateau and a sharp distal falloff. In order to make the beam as realistic
as possible and representative for a clinical beam, a Gaussian spread in en-
ergy and lateral position was implemented, making the distal dose falloff and
the lateral spread appear in good agreement with the Eclipse calculation for
dose deposited in a homogeneous water phantom. With the active method,
the beam can be programmed to be modulated in the desired fashion, lead-
ing to additional degrees of freedom compared to the passive method, which
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provides a more rigid and cumbersome modulation of the dose distribution.
An active method, not depending on extensive use of beamline hardware,
will be flexible and one can assume that in a clinical regime, an active beam
delivery can potentially be adaptive to changes in patient throughout the
treatment course.
Seven dose plans were created in FLUKA and in Eclipse. The geometry was
a water cube with and without an inhomogeneity made of either bone, air or
aluminium. The resulting dose profiles, lateral and in depth were compared,
as well as the 2D dose distribution. Dose profiles calculated for the phan-
toms containing a volume of material displayed some discrepancies between
FLUKA and Eclipse. In the position of the material volume, the dose profile
calculated by FLUKA yielded a change of dose level in the order of 5 % to
15 %, depending on the material, in addition to a change in the slope of the
depth dose curve. For the equivalent dose profile calculated by Eclipse, no
change in dose level was observed, however the depth dose curve did possess
the same change in slope as the dose profile calculated by FLUKA. Due to
the fact that the Eclipse algorithm only models water, all other materials are
scaled by density enhancement, there is a void with respect to the information
required to accurately predict the dose, or to predict the deposited energy in
the medium. The largest deviation with reference to the dose distribution in
a homogeneous water phantom, occurs when introducing aluminium into the
geometry. In Eclipse, the aluminium was represented in a volume of material
with a HU of +2800, which will correspond to the physical density for alu-
minium. Eclipse will interpret this as dense water, and hence an increase of
the slope of the dose distribution will occur. In FLUKA, the material will be
represented by its density, and in addition the parameters such as the mean
ionization energy and atomic number. Hence, FLUKA have all the informa-
tion necessary to, in a very accurate way, calculate the dose deposition by
the proton beam.
The stoichiometric method was developed in order to obtain an improved
relation between the CT HU value and the proton stopping power. The prin-
ciple method is to find the HU of various ICRU standard materials represent-
ing human tissue, and calculating the theoretical proton stopping power in
these tissues using the Bethe-Bloch equation, and by this find a one-to-one
relation between the two entities. One should note that this method is devel-
oped for use on human tissues, with densities and mean ionization energies in
the same order of magnitude as for water. When introducing non-biological
materials such as aluminium, the conversion from CT HU value to stopping
power is less accurate. For many clinical situations, metals and alloys are
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present in a patient to support or replace bone structures in the body. When
prescribing radiation therapy to patients with such implants one should avoid
irradiating through such structures.
Future Outlook FLUKA is a versatile tool and there are many challenges
that can be addressed, building upon the methods and results from this
project:
• In order to isolate the shortcomings of a given dose calculation algo-
rithm, one should apply the exact same geometry and beam set-up in
both the treatment planning system, and in the Monte Carlo module,
thus importing CT DICOM files into the FLUKA geometry.
• The beamline components will affect the beam entering the patient.
A realistic model of the beamline materials, geometry and dimensions
would provide additional information about the resulting dose profile.
• In order to create treatment plans in FLUKA that to an even larger de-
gree is mimicking the clinical beam, magnetic fields could be modelled
into the beam source.
• The effect of target movement.
• Other particles than protons and carbons, for instance helium- or lithium-
ions, should be studied.
• Quantitative studies of production of secondary particles, for instance
neutrons, for various modalities.
In addition to challenges addressed with the use of FLUKA, there are numer-
ous topics to study within the field of clinical dose planning. A comparison
between different commercial dose planning software on the market should
be studied, with the Monte Carlo simulations as a validation tool.
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Appendix A
Patient Statistics from PTCOG
123
Hadron Therapy Patient Statistics (data recieved from centers per end of March 2013)
Patient Statistics (for the facilities out of operation):
PARTICLE FIRST PATIENT LAST
PATIENT TOTAL PATIENT
Belgium Louvain-la-Neuve p 1991 21 1993 ocular tumors only
Canada Vancouver (TRIUMF) p- 1979 367 1994 ocular tumors only
Germany Darmstadt (GSI) C-ion 1997 440 2009
Japan Tsukuba (PMRC, 1) p 1983 700 2000
Japan Chiba p 1979 145 2002 ocular tumors only
Japan WERC p 2002 62 2009
Russia Dubna (1) p 1967 124 1996
Sweden Uppsala (1) p 1957 73 1976
Switzerland Villigen PSI (SIN-Piotron) p- 1980 503 1993
Switzerland Villigen PSI (OPTIS 1) p 1984 5458 2010 ocular tumors only
CA., USA Berkeley 184 p 1954 30 1957
CA., USA Berkeley He 1957 2054 1992
CA., USA Berkeley ion 1975 433 1992
IN., USA Bloomington (MPRI, 1) p 1993 34 1999 ocular tumors only
MA., USA Harvard p 1961 9116 2002
NM., USA Los Alamos p- 1974 230 1982
19790 Total
thereof 2054 He
1100 pions
440 C-ions
433 other ions
15763 protons
Patient Statistics (for facilities in operation end of 2012):
PARTICLE FIRST PATIENT DATE OF
PATIENT TOTAL TOTAL
Canada Vancouver (TRIUMF) p 1995 170 Dec-12  ocular tumors only
Czech Rep. Prag (PTCCZ) p 2012 1 Dec-12
China Wanjie (WPTC) p 2004 1078 Dec-12
China Lanzhou C ion 2006 194 Dec-12
England Clatterbridge p 1989 2297 Dec-12  ocular tumors only
France Nice (CAL) p 1991 4692 Dec-12  ocular tumors only
France Orsay (CPO) p 1991 5949 Dec-12   4748 ocular tumors
Germany Berlin (HMI) p 1998 2084 Dec-12  ocular tumors only
Germany Munich (RPTC) p 2009 1377 Dec-12
Germany HIT, Heidelberg C ion 2010 980 Dec-12
Germany HIT, Heidelberg p 2010 252 Dec-12
Italy Catania (INFN-LNS) p 2002 293 Nov-12  ocular tumors only
Italy Pavia (CNAO) p 2011 42 Dec-12
Italy Pavia (CNAO) C ion 2012 3 Dec-12
Japan Chiba (HIMAC) C ion 1994 7331 Jan-13   72 with scanning
Japan Kashiwa (NCC) p 1998 1226 Mar-13
Japan Hyogo (HIBMC) p 2001 3198 Dec-11
Japan Hyogo (HIBMC) C ion 2002 1271 Dec-11
Japan Tsukuba (PMRC, 2) p 2001 2516 Dec-12
Japan Shizuoka p 2003 1365 Dec-12
Japan Koriyama-City p 2008 1812 Dec-12
Japan Gunma C ion 2010 537 Dec-12
Japan Ibusuki (MMRI) p 2011 490 Dec-12
Korea Ilsan, Seoul p 2007 1041 Dec-12
Poland Krakow p 2011 15 Dec-12  ocular tumors only
Russia Moscow (ITEP) p 1969 4300 Dec-12   estimated
Russia St. Petersburg p 1975 1386 Dec-12
Russia Dubna (JINR, 2) p 1999 922 Dec-12
South Africa iThemba LABS p 1993 521 Dec-11
Sweden Uppsala (2) p 1989 1267 Dec-12
Switzerland Villigen-PSI, incl OPTIS2 p 1996 1409 Dec-12   498 ocular tumors
USA, CA. UCSF - CNL p 1994 1515 Dec-12  ocular tumors only
USA, CA. Loma Linda (LLUMC) p 1990 16884 Dec-12
USA, IN. Bloomington (IU Health PTC) p 2004 1688 Dec-12
USA, MA. Boston (NPTC) p 2001 6550 Oct-12
USA, TX. Houston (MD Anderson) p 2006 3909 Dec-12
USA, FL Jacksonville (UFPTI) p 2006 4272 Dec-12
USA, OK. Oklahoma City (ProCure PTC) p 2009 1045 Dec-12
USA, PA. Philadelphia (UPenn) p 2010 1100 Dec-12
USA, NY. New Jersey ProCure PTC) p 2012 137 Dec-12
USA, IL. CDH Warrenville p 2010 840 Dec-12
USA, VA. Hampton (HUPTI) p 2010 489 Dec-12
88448 Total
thereof 10316 C-ions
78132 protons
Total for all facilities (in operation and out of operation): 2054 He
1100 pions
10756 C-ions
433 other ions
93895 protons
108238 Grand Total
WHERE
WHERE
March 2013  - Martin Jermann, PTCOG Secretary
Appendix B
FLUKA Script
B.1 Input Card 1
Input for the simulations used to determine the range in the phantom with
heterogeneities.
TITLE
* Set the defaults for precision simulations
DEFAULTS HADROTHE
* Define the beam characteristics
BEAM -0.1 -0.6 -0.6 PROTON
* Define the beam position
BEAMPOS -1.
GEOBEGIN COMBNAME
0 0
* Black body
SPH blkbody 0.0 0.0 0.0 100000.0
* Void sphere
SPH void 0.0 0.0 0.0 10000.0
RPP vann -10. 10. -10. 10. 0.0 20.
RPP bein -0.5 0.5 -0.5 0.5 5.0 6.0
END
* Black hole
BLKBODY 5 +blkbody -void
* Void around
VOID 5 +void -vann
* Target
TARGET 5 +vann -bein
bein 5 +bein
END
GEOEND
MATERIAL 15. 30.973761 1.82 PHOSPHO
* Cort. Bone Ages 2-5
* from: Woodward and White, Brit. J. Radiology, vol. 59, 1216 (1986).
MATERIAL 1.8 Cortical
COMPOUND -20.1 CALCIUM -10.1 PHOSPHO -4.0 HYDROGENCortical
COMPOUND -15.7 CARBON -4.5 NITROGEN -45.4 OXYGENCortical
COMPOUND -0.2 MAGNESIU Cortical
* ..+....1....+....2....+....3....+....4....+....5....+....6....+....7..
ASSIGNMA BLCKHOLE BLKBODY
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ASSIGNMA AIR VOID
ASSIGNMA WATER TARGET
ASSIGNMA Cortical bein
USRBIN 10. DOSE -41. 12. 12. 22.Dose
USRBIN -12. -12. -2. 250. 250. 250. &
* Set the random number seed
RANDOMIZ 1.0
* Set the number of primary histories to be simulated in the run
START 10000.
STOP
B.2 Surce.f code to produce SOBP
*$ CREATE SOURCE.FOR
*COPY SOURCE
*
*=== source ===========================================================*
*
SUBROUTINE SOURCE ( NOMORE )
INCLUDE ’(DBLPRC)’
INCLUDE ’(DIMPAR)’
INCLUDE ’(IOUNIT)’
*----------------------------------------------------------------------*
*
*
DIMENSION CUMPR(0:51), ENEDGE(52)
*----------------------------------------------------------------------*
*
INCLUDE ’(BEAMCM)’
INCLUDE ’(CASLIM)’
INCLUDE ’(FHEAVY)’
INCLUDE ’(FLKSTK)’
INCLUDE ’(IOIOCM)’
INCLUDE ’(LTCLCM)’
INCLUDE ’(PAPROP)’
INCLUDE ’(SOURCM)’
INCLUDE ’(SUMCOU)’
*
LOGICAL LFIRST
SAVE LFIRST
DATA LFIRST / .TRUE. /
*----------------------------------------------------------------------*
* Proton energy group boundaries
DATA ENEDGE /
& 116.5273483522E-03,
& 116.8572207934E-03,
& 117.511318736E-03,
& 118.1626328485E-03,
& 118.8112018355E-03,
& 119.4570634973E-03,
& 120.1002547594E-03,
& 120.7408117005E-03,
& 121.3787695801E-03,
& 122.0141628644E-03,
& 122.6470252507E-03,
& 123.2773896923E-03,
& 123.9052884206E-03,
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& 124.5307529678E-03,
& 125.1538141879E-03,
& 125.7745022769E-03,
& 126.3928467928E-03,
& 127.0088766743E-03,
& 127.6226202587E-03,
& 128.2341052997E-03,
& 128.8433589843E-03,
& 129.4504079485E-03,
& 130.0552782933E-03,
& 130.6579955999E-03,
& 131.2585849436E-03,
& 131.8570709084E-03,
& 132.4534776E-03,
& 133.0478286592E-03,
& 133.6401472743E-03,
& 134.230456193E-03,
& 134.8187777345E-03,
& 135.4051338006E-03,
& 135.9895458867E-03,
& 136.5720350922E-03,
& 137.1526221309E-03,
& 137.7313273407E-03,
& 138.3081706934E-03,
& 138.8831718036E-03,
& 139.456349938E-03,
& 140.0277240236E-03,
& 140.5973126567E-03,
& 141.1651341103E-03,
& 141.7312063425E-03,
& 142.295547004E-03,
& 142.8581734451E-03,
& 143.4191027234E-03,
& 143.9783516104E-03,
& 144.5359365983E-03,
& 145.0918739064E-03,
& 145.6461794876E-03,
& 146.1988690346E-03,
& 146.5259180059E-03/
* Cumulative spectrum
DATA CUMPR / 0.D0,
*...+....1....+....2....+....3....+....4....+....5....+....6....+....7..
& 0.0037617826,
& 0.0113572171,
& 0.0190511735,
& 0.026847045,
& 0.0347484179,
& 0.0427590866,
& 0.0508830711,
& 0.0591246358,
& 0.0674883104,
& 0.0759789135,
& 0.0846015784,
& 0.0933617824,
& 0.1022653795,
& 0.1113186368,
& 0.1205282764,
& 0.1299015219,
& 0.1394461518,
& 0.14917056,
& 0.1590838253,
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& 0.1691957909,
& 0.1795171563,
& 0.1900595838,
& 0.2008358222,
& 0.211859852,
& 0.2231470558,
& 0.2347144202,
& 0.246580777,
& 0.2587670911,
& 0.2712968098,
& 0.2841962879,
& 0.2974953106,
& 0.311227742,
& 0.3254323398,
& 0.3401537886,
& 0.3554440301,
& 0.3713639983,
& 0.3879859229,
& 0.4053964425,
& 0.4237009038,
& 0.4430294459,
& 0.4635458611,
& 0.4854609439,
& 0.5090534391,
& 0.5347046021,
& 0.5629589238,
& 0.5946399536,
& 0.6310973585,
& 0.6748275437,
& 0.7315147259,
& 0.822172059,
& 1/
*----------------------------------------------------------------------*
*...+....1....+....2....+....3....+....4....+....5....+....6....+....7..
*----------------------------------------------------------------------*
NOMORE = 0
* +-------------------------------------------------------------------*
* | First call initializations:
IF ( LFIRST ) THEN
* | *** The following 3 cards are mandatory ***
TKESUM = ZERZER
LFIRST = .FALSE.
LUSSRC = .TRUE.
* | *** User initialization ***
END IF
* |
* +-------------------------------------------------------------------*
* In order to cover the target volume in depth the energy must be
* sampled from the ENEDGE, with cumulative weights from CUMPR
* Sample the energy group
XI = FLRNDM(DUMMY)
DO 500 K = 1, 52
IF(XI .LE. CUMPR(K)) THEN
ENERGY = ENEDGE(K) -
& (XI-CUMPR(K-1))*(ENEDGE(K)-ENEDGE(K+1))/(CUMPR(K)-CUMPR(K-1))
GO TO 600
END IF
500 CONTINUE
STOP ’ Failed to sample the energy group’
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600 CONTINUE
kount=kount+1
*
* Npflka is the stack counter: of course any time source is called it
* must be =0
NPFLKA = NPFLKA + 1
* Wt is the weight of the particle
WTFLK (NPFLKA) = ONEONE
WEIPRI = WEIPRI + WTFLK (NPFLKA)
* Particle type (1=proton.....). Ijbeam is the type set by the BEAM
* card
* +-------------------------------------------------------------------*
* | Heavy ion:
IF ( IJBEAM .EQ. -2 ) THEN
IJHION = IPROZ * 1000 + IPROA
IJHION = IJHION * 100 + KXHEAV
IONID = IJHION
CALL DCDION ( IONID )
CALL SETION ( IONID )
ILOFLK (NPFLKA) = IJHION
* |
* +-------------------------------------------------------------------*
* | Normal hadron:
ELSE
IONID = IJBEAM
ILOFLK (NPFLKA) = IJBEAM
END IF
* |
* +-------------------------------------------------------------------*
* From this point .....
* Particle generation (1 for primaries)
LOFLK (NPFLKA) = 1
* User dependent flag:
LOUSE (NPFLKA) = 0
* User dependent spare variables:
DO 100 ISPR = 1, MKBMX1
SPAREK (ISPR,NPFLKA) = ZERZER
100 CONTINUE
* User dependent spare flags:
DO 200 ISPR = 1, MKBMX2
ISPARK (ISPR,NPFLKA) = 0
200 CONTINUE
* Save the track number of the stack particle:
ISPARK (MKBMX2,NPFLKA) = NPFLKA
NPARMA = NPARMA + 1
NUMPAR (NPFLKA) = NPARMA
NEVENT (NPFLKA) = 0
DFNEAR (NPFLKA) = +ZERZER
* ... to this point: don’t change anything
* Particle age (s)
AGESTK (NPFLKA) = +ZERZER
AKNSHR (NPFLKA) = -TWOTWO
* Group number for "low" energy neutrons
IGROUP (NPFLKA) = NEUGRP
* Kinetic energy of the particle (GeV)
* With Gaussian sigma 0.008 GeV
CALL FLNRRN (RGAUSS)
TKEFLK (NPFLKA) = ENERGY*(1+0.008D0*RGAUSS)
* Particle momentum
PMOFLK (NPFLKA) = SQRT ( TKEFLK (NPFLKA) * ( TKEFLK (NPFLKA)
* + TWOTWO * AM (ILOFLK(NPFLKA)) ) )
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* Cosines (tx,ty,tz)
TXFLK (NPFLKA) = UBEAM
TYFLK (NPFLKA) = VBEAM
TZFLK (NPFLKA) = WBEAM
* TZFLK (NPFLKA) = SQRT ( ONEONE - TXFLK (NPFLKA)**2
* & - TYFLK (NPFLKA)**2 )
* Polarization cosines:
TXPOL (NPFLKA) = -TWOTWO
TYPOL (NPFLKA) = +ZERZER
TZPOL (NPFLKA) = +ZERZER
* Particle coordinates
* cover the volume in X and Y direction
* Gaussiuan sigma 0.37 cm to account for lateral spread in beam
CALL FLNRR2(RGAUS1, RGAUS2)
XFLK (NPFLKA) = (-2.7 + 0.37D0*RGAUS1)+ FLRNDM(DUMMY)*5.4
YFLK (NPFLKA) = (-2.7 + 0.37D0*RGAUS2)+ FLRNDM(DUMMY)*5.4
ZFLK (NPFLKA) = -1.0
* Calculate the total kinetic energy of the primaries: don’t change
IF ( ILOFLK (NPFLKA) .EQ. -2 .OR. ILOFLK (NPFLKA) .GT. 100000 )
& THEN
TKESUM = TKESUM + TKEFLK (NPFLKA) * WTFLK (NPFLKA)
ELSE IF ( ILOFLK (NPFLKA) .NE. 0 ) THEN
TKESUM = TKESUM + ( TKEFLK (NPFLKA) + AMDISC (ILOFLK(NPFLKA)) )
& * WTFLK (NPFLKA)
ELSE
TKESUM = TKESUM + TKEFLK (NPFLKA) * WTFLK (NPFLKA)
END IF
* Flag this is prompt radiation
LRADDC (NPFLKA) = .FALSE.
RADDLY (NPFLKA) = ZERZER
* Here we ask for the region number of the hitting point.
* NREG (NPFLKA) = ...
* The following line makes the starting region search much more
* robust if particles are starting very close to a boundary:
CALL GEOCRS ( TXFLK (NPFLKA), TYFLK (NPFLKA), TZFLK (NPFLKA) )
CALL GEOREG ( XFLK (NPFLKA), YFLK (NPFLKA), ZFLK (NPFLKA),
& NRGFLK(NPFLKA), IDISC )
* Do not change these cards:
CALL GEOHSM ( NHSPNT (NPFLKA), 1, -11, MLATTC )
NLATTC (NPFLKA) = MLATTC
CMPATH (NPFLKA) = ZERZER
CALL SOEVSV
RETURN
*=== End of subroutine Source =========================================*
END
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